The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.

Description

46 parts

›BACKGROUND OF THE INVENTION

Laminins are a family of basement membrane proteins which function in cell differentiation, adhesion, and migration, in addition to being true structural components (Tryggvason K, Curr. Opn. Cell Biol., 1993, 5:877-882, this and all following references are hereby incorporated by reference). The laminin molecule is a cross-shaped heterotrimer consisting of one heavy chain (˜400 kd) and two light chains, β and γ (130-200 kd) (nomenclature according to Burgeson et al., Matrix Biol., 1994, 14:209-211). Laminin exists in numerous isoforms that are formed by different combinations of laminin chain variants which currently amount to at least nine.

Kalinin/laminin 5 (most likely also identical to the adhesion molecule nicein) is a recently identified laminin isoform which is a functional adhesion component for epithelial cells (Tryggvason, 1993, supra.; Burgeson et al., 1994, supra.; Rousselle et al., J. Cell Biol., 1991, 114:567-576; Kallunki et al., J. Cell Biol., 1992, 119:679-693; Marinkovich et al., J. Biol. Chem., 1992, 267:17900-17906; Vailly et al., Eur. J. Biochem., 1994, 219:209-218). Kalinin/laminin 5 contains unique laminin variant chains, one of which, the γ2 chain, has recently been cloned and sequenced (Kallunki et al., 1992, supra., previously named B2t). The γ2 chain has a mass of ˜130 kd and is thus smaller than the "classical" ˜200 kd β1 and γ1 light chains of laminin. The domain structure of the γ2 chain also differs from that of the γ1 chain in that it lacks the amino-terminal globular domain (domain VI) believed to function in intermolecular cross-linking of laminin molecules to form networks (Yurcheno and O'Rear, in Molecular and Celluar Aspects of Basement Membranes, 1993, (ed. Rohrbach and Timpl, Academic Press, San Diego, pp. 20-47). In addition, domains III, IV, and V (containing EGF-like repeats) in γ2 are shorter than in the γ1 chain (Kallunki et al., 1992, supra.).

By in situ hybridization the γ2 chain was found to be expressed in epithelial cells of many embryonic tissues such as those of skin, lung, and kidney (Kallunki et al., 1992, supra.), and antibodies to kalinin/laminin 5, react with basement membranes of the same tissues (Rousselle et al., 1991, supra.; Verrando et al., Lab. Invest., 1991, 64:85-92).

The different laminin chains have been shown to have quite varying tissue distribution as determined by immunohistological studies, Northern, and in situ hybridization analyses. For example, the A and M chains on the one hand, and the B1 (β1) and S (β2) chains on the other, have been shown to be mutually exclusive (see for example Vuolteenaho et al., J. Cell Biol., 1994, 124:381-394). In vitro studies have indicated that laminin mediates a variety of biological functions such as stimulation of cell proliferation, cell adhesion, differentiation, and neurite outgrowth. The cellular activities are thought to be mediated by cell memebrane receptors, many of which are members of the integrin family (Ruoslahti, E. J. Clin. Invest., 1991, 87:1-5; Mecham, R. P. FASEB J., 1991, 5:2538-2546; Hynes, R. Cell, 1992, 69:11-25).

Recently a new nomenclature for describing laminins has been agreed to as in the following Table 1 (after Burgeson et al., 1994, supra.)

______________________________________

laminin chains and genes

heterotrimers of laminin

New Previous Gene New Chains

______________________________________

α1

A, Ae LAMA1 laminin-1

α1β1γ1

EHS laminin

α2

M, Am LAMA2 laminin-2

α2β1γ1

merosin

α3

200 kDa LAMA3 laminin-3

α1β2γ1

s-laminin

β1

B1, B1e LAMB1 laminin-4

α2β2γ1

s-merosin

β2

S, B1s LAMB2 laminin-5

α3β3γ2

kalinin/nicein

β3

140 kDa LAMB3 laminin-6

α3β1γ1

k-laminin

γ1

B2, B2e LAMC1 laminin-7

α3β2γ1

ks-laminin

γ2

B2t LAMC2

______________________________________

›SUMMARY OF THE INVENTION

The instant invention provides for methods of detecting kalinin/laminin 5 expression in tissue comprising detecting a signal from assayed tissue, such signal resulting from specifically hybridizing tissue with an effective amount of a nucleic acid probe, which probe contains a sense or antisense portion of kalinin/laminin 5 gamma-2 nucleic acid sequence (Kallunki et al., 1992, supra.). In particular, where the nucleic acid probe is DNA, RNA, radiolabelled, enzyme labelled, chemiluminescent labelled, avidin or biotin labelled, derived from human kalinin/laminin 5 gamma-2 nucleic acid sequence, incorporated into an extrachromasomal self-replicating vector, a viral vector, is linear, circularized, or contiains modified nucleotides. In the preferred embodiment the probes are linearized specific regions of the γ2 gene.

The instant invention also provides for methods for detecting the presence of invasive cells in tissue comprising detecting a signal from assayed tissue, such signal resulting from contacting tissue with an effective amount of a nucleic acid probe, which probe contains a sense or antisense portion of kalinin/laminin 5 gamma-2 nucleic acid sequence (Kallunki et al., 1992, supra.). In particular, where the nucleic acid probe is DNA, RNA, radiolabelled, enzyme labelled, chemiluminescent labelled, avidin or biotin labelled, derived from human kalinin/laminin 5 gamma-2 nucleic acid sequence, incorporated into an extrachromasomal self-replicating vector, a viral vector, is linear, circularized, or contiains modified nucleotides. In the preferred embodiment the probes are linearized specific regions of the γ2 gene. The instant method also provides for the diagnosis of the absence of γ2 chain expression, useful for the monitoring of therapies, and the progress of malignant cell transformation leading to accurate determination of the extent of invasive cell activity.

The instant invention further provides for a method for detecting kalinin/laminin 5 expression in tissue comprising detecting a signal from assayed tissue, such signal resulting from contacting tissue with an effective amount of a labeled probe, which probe contains an antibody immunoreactive with a portion of kalinin/laminin 5 gamma-2 protein.

Further provided is a method for detecting invasive cells in tissue comprising detecting a signal from assayed tissue, such signal resulting from contacting tissue with an effective amount of a labeled probe, which probe contains an antibody immunoreactive with a portion of kalinin/laminin 5 gamma-2 protein. Also provided is a method for detecting kalinin/laminin 5 in tissue comprising detecting a signal from assayed tissue, such signal resulting from contacting tissue with an effective amount of a labeled probe, which probe contains an antibody immunoreactive with a potion of kalinin/laminin 5 gamma-2 protein. Thus the method of the instant invention provides for the absence of such signal as diagnostic for the absence of invasive cells.

›BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A,B,C,D shows in situ hybridization of a specimen of colon adenocarcinoma for γ2 chain mRNA using a S-35 labeled anti-sense RNA probe derived from plasmid pbb2r-02. Magnification:1A×100; 1B-1D×640.

FIGs. 2A-D shows in situ hybridization for γ2 chain mRNA on sections of ductal mammary carcinoma (2A), malignant melanoma (2B), squamous cell carcinoma of the skin (2C-2D), and squamous cell carcinoma of the vulva (2E-2G). Magnification: 2C×100, all others ×640. Photos marked by plain letter ie. X, show in situ hybridization results for γ2 chain mRNA on stained sections. Photos marked by the apostrophe letter, ie. X', are the dark field images of the respective photomicographs.

FIGS. 3A,A' is incisionally wounded mouse skin (72 hours after wounding) showing signal for γ2 chain in keratinocytes at the leading edge of the migrating epithelium (curved arrow). Magnification:×640. FIG. 3A is a photo of in situ hybridization on a stained section showing γ2 chain signal. FIG. 3A' is a photo showing the dark field image of 3A.

FIGS. 4A-B shows the nucleic acid sequence for the γ2 chain cDNA and the derived amino acid sequence. FIG. 4A is the full cDNA for the 5,200 base pair sequence, availible from EMB/GenBank/DDBJ under the accession number Z15008. FIG. 4B is the nucleotide and derived amino acid sequence of the alternative 3' end sequence from cDNA clones providing a sequence of 4,316 base pairs, availible from EMB/GenBank/DDBJ under the accession number Z15009. (Kallunki et al.,1992, supra.) SEQ ID NOs:12,13,14 & 15.

›DETAILED DESCRIPTION OF THE INVENTION · 1 of 2

Epidermolysis bullosa (EB) is a group of mechano-bullous disorders characterized by fragility of the skin and mucous membranes (see Lin & Carter eds., Epidermolysis bullosa. Basic and clinical aspects, 1992, Springer Verlag, N.Y.; Fine et al., J. Am. Acad. Dermatol., 1991, 24:119-135). The junctional forms of EB (JEB) are characterized by tissue separation at the level of the lamina lucida within the dermal-epidermal basement membrane, and no specific mutation had yet to be reported. Recently it has been proposed that the genes for a lamina lucida protein kalinin/nicein/epiligin may be a candidate in some forms of JEB (Verrando et al., 1991, supra.). Several lines of evidence suggest that anchoring filament proteins could be defective in some forms of JEB. First, attenuation or absence of immunoreactivity with anti-kalinin(epiligrin) antibodies has been noted in the skin of patients with the most severe (Herlitz) type of JEB. The immunofluorescence staining patterns may be of prognostic value in classifying JEB, and these immunoreagents have been used for prenatal diagnosis of JEB using fetal skin biopsy specimens. Second, the kalinin/laminin 5 γ2 chain is expressed in epithelial cells of the skin, trachea and kidneys, tissues which are frequently affected by JEB.

Since the majority of cases are of the generalized (Herlitz) phenotype (H-JEB), JEB patients have been classified into Herlitz and non-Herlitz types. Clinical features of H-JEB include mechanical fragility of the skin, with widespread blistering and erosions, rapid deterioration and neonatal death, often from sepsis. Longterm survival is rare.

Efforts to identify the basic defect in JEB began with the observation that a monoclonal antibody that binds to the lamina lucida of the epidermal basement membrane zone of normal skin, fails to react with the lamina lucida of H-JEB skin (Verrando et al., 1991, supra.). The antigen recognized by this antibody was purified from keratinocyte culture medium and termed BM600/nicein. Keratinocytes cultured from the skin of H-JEB patients attach poorly to substrate and fail to accumulate immunologically detectable nicein. Further experiments with antibodies specific for the α3 chain of nicein, demonstrated that they were capable of inducing the rounding and detachment of adherent keratinocytes without affecting fibroblasts (Rousselle et al., 1991, supra.). Thus the correlation in vivo and in vitro of the dermoepidermal separation with deficient nicein/kalinin/laminin 5 immunoreactivity and the separation induced by anti-nicein antibody have made the genes encoding this protein strong candidates for the site of H-JEB mutations.

The importance of the γ2 chain of nicein/kalinin/laminin 5 in JEB, and epithelial tissues prompted the investigation into the role such adhesion contacts between epithelial cells may play in abberant cells. Of primary interest was the role γ2 chain of nicein/kalinin/laminin 5 abberant expression may play in cancer tissue, and a possible role in cancer dissemination.

It has been recently shown that in colon adenocarcinoma, a significant positive correlation between the degree of tumor budding and the recurrence of tumors following. curative surgery exists, and that this fact is likely to reflect a higher invasive potential of budding cancer cells as compared with cancer cells located deeper in the tumor (Hase et al., Dis. Colon Rectum, 1993, 36:627-635). Therefore, as demonstrated in Example 3 below, the instant invention allows for the useful prognostic determination of success of surgery, means for monitoring progression of rumor budding and subsequent prognosis.

The identification of the role of γ2 chain allows for the novel use of kalinin/laminin 5 γ2 chain and its ligand, as diagnostic probes of the tumor cell/basement membrane adhesion interface that is crucial for the invasion of non-malignant tissues, and identifies invasive cells.

Thus the identification of the role of γ2 chain allows for the novel therapeutic intervention of binding of kalinin/laminin 5 to its ligand, and thereby reducing the tumor cell/basement membrane adhesion that is crucial for the invasion of non-malignant tissues, and method for inhibiting the budding of tumor masses, and a means for determing the level of γ2 chain expression as a measure of budding activity of a given tumor.

As demonstrated in Example 3 below, the γ2 chain of kalinin/laminin 5 is preferentially expressed by invasively growing malignant cells in human carcinomas. Furthermore, migrating keratinocytes in wound healing also expressed this gene, pointing to a role of γ2 chain in epithelial cell migration both in malignant and in nonmalignant pathological conditions. The consistent expression of the γ2 chain gene in invading cancer cells reflects a functional importance of this molecule in vivo in establishing contacts between the invading malignant cells and a provisional matrix in the immediate surroundings of the cancer cells. The instant invention provides methods for the identification of, and diagnosis of invasive cells and tissues, and for the monitoring of the progress of therapeutic treatments.

In a preferred embodiment of this aspect of the instant invention the nucleic acid probe comprise a specifically hybridizing fragment of the γ2 chain cDNA nucleic acid sequence. In this embodiment, the nucleic acid sequence comprises all or a specifically hybridizing fragment of an open reading frame of the nucleic acid sequence for the γ2 chain (FIG. 4) encoding the amino acid sequence of the γ2 chain (FIG. 4). It will be understood that the term "specifically hybridizing" when used to describe a fragment of nueleic acid encoding a human laminin γ2 chain gene is intended to mean that, nueleic acid hybridization of such a fragment is stable under high stringency conditions of hybridization and washing as the term "high stringency" would be understood by those having skill in the molecular biological arts.

Further, the instant invention provides for the therapeutic treatment of such invasive tissues by using γ2 chain or biologically active fragments thereof to interfere with the interactions between abberant γ2 chain and surrounding tissues. The instant invention also provides for the intervention of γ2 chain interaction with surrounding tissues by using specific anti-γ2 chain antibodies (monoclonal or polyclonal) to inhibit the γ2 chain biological activity.

›DETAILED DESCRIPTION OF THE INVENTION · 2 of 2

The instant disclosure also allows one to ablate the invasive cell phenotypic γ2 chain expression by using genetic manipulation to "knock-out" the functional expression of the γ2 chain gene in cancer cells, or to completely "knock-out" the functional γ2 chain gene in the genome of cancer cells. Such knock-outs can be accomplished by using genetic molecular biological techniques for inserting by homologous recombination into genomic DNA, targeted transposon insertion, or random insertion/deletion mutations in the genomic DNA.

The instant disclosure also allows for the therapeutic treatment of invasive cell phenotype by the inhibition of functional γ2 chain expression in targeted cells by using anti-sense technology, such methods for anti-sense production, stabilization, delivery, and therapeutic approaches are reviewed in Uhlmann et al., 1990, Chem. Reviews 90:543-584).

Thus the instant invention provides for a method of detection, diagnosis, prognosis, monitoring, and therapeutic treatment of invasive cell phenotypes.

The examples below are meant by way of illustration, and are not meant to be limiting as to the scope of the instant disclosure.

›Examples6

›EXAMPLE 1

Mutation in the γ2 Chain Gene LAMC2 is critical in some cases of JEB

A unique scanning strategy using RT-PCR amplification of LAMC2 sequences was devised to detect truncated forms of γ2 chain gene transcripts (Pulkkinen et al., Nature Genetics, 1994, 6:293-298). The 3.6 kilobase coding sequence of the LAMC2 mRNA, was reverse transcribed and amplified with eight pairs of primers, producing overlapping PCR amplimers designated A-H. The PCR products were then examined by agarose gel electrophoresis, followed by MDE heteroduplex analysis. If bands with altered mobility were detected, the PCR products were sequenced, and compared with normal sequences from unaffected family members or unrelated individuals. Intron/exon borders were identified by PCR analysis of genomic DNA, deduced by comparison with cDNA sequences.

A point mutation produces exon skipping

When a panel of five unrelated JEB patients were analysed, the primers used to amplify segment C (nt 1046-1537) produced a markedly shortened band of 273 base pairs, as compared with the normal 491 base pairs. No evidence of the normal sized band was noted, suggesting that the patient was homozygous for this allele. Direct sequencing revealed that the shortened product resulted from the deletion of 219 base pairs corresponding to nucleotides 1184-1402 in the cDNA, thus exon 9 was deleted. The remaining nucleotide sequences within this and other PCR products did not reveal any additional mutations upon MDE analysis.

Subsequent examination of the genomic DNA revealed that the sequences for exons 8, 9 and 10 were present, however a homozygous G for A substitution at the 3' acceptor splice site at the junction of intron 8 and exon 9, abolished the obligatory splice site sequence (AG).

Examination of another patient revealed that PCR product F (nt 2248-2777) corresponding to domains I and II of the γ2 chain, was a band with altered mobility. Sequencing the abnormal product revealed a 20 bp deletion, followed by a single base pair (G) insertion in the coding region corresponding to exon 16. This mutation causes a frameshift which results in a premature stop codon 51 base pairs downstream from the deletion-insertion, producing a truncated kalinin/laminin 5 γ2 chain terminating at residue 830.

RT-PCR and MDE analyses

RNA isolated from fibroblast cell cultures of JEB patients was used as template for RT-PCR of the LAMC2 mRNA. (Epidermal keratinocytes can also be used). cDNA was prepared from 50 μg of total RNA in a volume of 100 μL according to manufacturer's reccomendations (BRL), and oligonucleotide primers were synthesized on the basis of the cDNA sequence (FIG. 4; Kallunki et al., 1992, supra.), to generate ˜500 base pair products, which spanned the entire coding region.

For PCR amplification, 1 μL of cDNA was used as template and amplification conditions were 94° C. for 5 min followed by 95° C. for 45 sec, 60° C. for 45 sec and 72° C. for 45 sec for 35 cycles in an OmniGene thermal cycler (Marsh Scientific). Amplification was performed in a total volume of 25 μL containing 1.5 mM MgCl 2 , and 2 U Taq polymerase (Boehringer Mannheim). Aliquots of 5 μL were analysed on 2% agarose gels and MDE heteroduplex analysis was performed according to the manufacturer's reccomendation (AT Biochemicals). Heteroduplexes were visualized by staining with ethidium bromide. If a band of altered mobility was detected in heteroduplex analysis, the PCR product was subcloned into the TA vector (Invitrogen), and sequenced by standard techniques.

DNA isolated either from fibroblast cultures or from specimens obtained from buccal smears, was used as template for amplification of genomic sequences. For amplification of introns 8 and 16, ˜500 ng of genomic DNA was used as template and the following oligomer primers were utilized.

5' GGCTCACCAAGACTTACACA 3' (SEQ ID NO:1);

5' GAATCACTGAGCAGCTGAAC 3' (SEQ ID NO:2);

5' CAGTACCAGAACCGAGTTCG 3' (SEQ ID NO:3);

5' CTGGTTACCAGGCTTGAGAG 3' (SEQ ID NO:4);

5' TTACTGCGGAATCTCACAGC 3' (SEQ ID NO:5);

5' TACACTGTTCAACCCAGGGT 3' (SEQ ID NO:6);

5' AAACAAGCCCTCTCACTGGT 3' (SEQ ID NO:7);

5' GCGGAGACTGTGCTGATAAG 3' (SEQ ID NO:8);

5' CATACCTCTCTACATGGCAT 3' (SEQ ID NO:9);

5' AGTCTCGCTGAATCTCTCTT 3' (SEQ ID NO:10);

5' TTACAACTAGCATGGTGCCC 3' (SEQ ID NO:11);

Amplification conditions were 94° C. for 7 min followed by 95° C. for 1.5 min, 56° C. (intron 8) or 58° C. (intron 16) for 1 min and 72° C. for 1.5 min for 35 cycles in an OmniGene thermal cycler (Marsh Scientific). Amplification was performed in a total volume of 25 μL containing 1.5 mM MgCl 2 , and 2 U Taq polymerase (Boehringer Mannheim). The PCR products were subcloned and sequenced as above.

Verification of Mutations

The putative mutations detected in the PCR products were verified at the genomic level in both cases. For this purpose, a search for a potential change in restriction endonuclease sites as a result of the mutation was performed.

Amplification conditions were 94° C. for 7 min followed by 94° C. for 1 min, 58° C. for 45 sec and 72° C. for 45 sec for 35 cycles in an OmniGene thermal cycler (Marsh Scientific). PCR products were analysed on 2.5% agarose gels.

The methods described allow for the screening of patients for mutations in the γ2 chain which will correlate with JEB. As demonstrated, the results have identified a homozygous point mutation resulting in oxon skipping, and a heterozygous deletion-insertion mutation. This demonstrating the effective screening for, and identification of, γ2 chain mutations which correlate with JEB. The methods are thus useful for diagnosis, prenatal screening, early screening and detection, as well as detailed examination of JEB. Further, the results show that the functional role of γ2 chain expression in epithelial cells is important in determining proper intercellular connectivity, relating to the integrity of tissues and cell interactions.

›EXAMPLE 2 · 1 of 2

Mutation in the γ2 Chain Gene LAMC2 is Critical in H-JEB

The correlation both in vivo and in vitro of the dermo-epidermal separation in H-JEB, with deficient immunoreactivity of anti-nicein/kalinin/laminin 5 antibodies, and the separation induced by anti-nicein/kalinin/laminin 5 antibodies have made the genes encoding this protein strong candidates for the site of H-JEB mutations. In this example, it is demonstrated that the molecular defect which causes H-JEB is linked to the gene encoding nicein/kalinin/laminin 5 γ2 chain. In particular, the occurence of a homozygous premature termination codon mutation is the specific cause in an examined case of H-JEB (Aberdam et al., Nature Genetics, 1994, 6:299-304).

Expression of mRNA encoding the three nicein subunits by northern analysis of RNA isolated from primary keratinocyte culture of a H-JEB patient was determined as the initial screen. Hybridization with probes for the α3 and β3 subunits was normal, but no hybridization with a cDNA encoding the γ2 subunit was detected. Examination of the genomic DNA for gross abnormalities, such as large deletions, insertions or rearrangements, in LAMC2 (the γ2 subunit gene) by Southern blot analysis turned up no abnormalities when the genomic DNA was digested with BamHI, BglI, HindIII, PstI or PvuII and probed with full length LAMC2 cDNA.

Possible mutations in the γ2 subunit were sought by using cDNA reverse transcribed from total RNA purified from cultured keratinocytes of the H-JEB patient, and subjected to PCR amplification. The size of the amplified products was checked by electrophoresis on 2% agarose gels and compared with that obtained from healthy controls.

No major differences were detected in the agarose gels, and the PCR products were examined by heteroduplex analysis (MDE). Heteroduplex analysis of the most 5' PCR product (nt 35-726) revealed the presence of a homoduplex in the proband (pateint) and the controls. However, when the amplified PCR products from the patient and control were mixed together, an additional band with altered mobility, representing heteroduplexes, was detected, suggesting a homozygous mutation in the patient's LAMC2 cDNA. This amplified fragment corresponded to domain V of the γ2 protein (Vailly et al., Eur. J. Biochem., 1994, 219:209-218). Sequencing detected a C to T transition at position +283, leading to a nonsense mutation in which a termination codon TGA replaces an arginine (CGA), perhaps arising as a result of the hypermutability of 5-methyl-cytosine to thymine at CpG nucleotides. This mutation, R95X, leads to truncation of the γ2 subunit polypeptide at amino acid 95 and loss of a TaqI restriction site (TCGA). Digestion of cDNA with TaqI confirmed the presence of a homozygous mutation in the DNA of the H-JEB patient. No other mutations were detected.

To confirm the cosegregation of the mutation with the loss of the TaqI restriction site, eight genotyped individuals of the family of the patient were screened. In each case, a 120 base pair fragment was amplified by PCR using genomic DNA templates and primers flanking the restriction site. Upon digestion of the wild type amplification product, two clevage fragments of 80 and 40 base pairs are generated. Consistent with the presence of a heterozygous mutation in carriers of this genotype, DNA fragments of 120, 80 and 40 base pairs, indicative of a wild type genotype, were found in the paternal grandmother and two other relatives.

Cell Culture

Epidermis was separated from dermis by dispase treatment at 37 C. Keratinocytes were dissociated in 0.25% trypsin at 37° C. and plated onto a feeder layer of irradiated mouse 3T3 cells (ICN) (Rheinwald & Green, Cell, 175, 6:331-334). Keratinocytes were grown in a 1:1 mixture of DMEM and Ham's F12 (BRL) containing 10% Fetal Calf Serum (FCS), 1 mM sodium pyruvate, 2 mM L-glutamine, 10 μg/mL of penicillin and strptomycin, 10 ng/mL transferrin, 180 μM adenine and 20 pM T3 (Simon & Green, Cell, 1985, 40:677-683). H-JEB keratinocytes were expanded after gentle dissociation in 0.05% trypsin, 0.02% EDTA.

Northern Blot Analysis

Total RNA was prepared from H-JEB and normal cultured keratinocytes according to standard methods (Chomzynski & Sacchi, Anal. Biochem., 1987, 162: 156-159). RNA was electrophoresed in 1.2% denaturing agarose gels containing 1.2M formaldehyde and transferred onto Hybond N membrane (Amersham). Membranes were hybridized at high stringency with P-32 labeled cDNA probes corresponding to the different chains of nicein, and then exposed on Hyperfilm MP (Amersham) with intensifying screens. Radiolabeled cDNA probes NA1 (Baudoin et al., J. Invest. Dermatol., 1994, in press), KAL-5.5C (Gerecke et al., Eur. J. Biochem., 1994, in press), and PCR 1.3 (Vailly et al., 1994, supra.), were used to detect the mRNAs for nicein chains α3, β3 and γ2, respectively.

RT-PCR and heteroduplex analysis (MDE)

50 μg of total RNA isolated from cultured keratinocytes from JEB patient, and unrelated healthy controls were reverse transcribed in a volume of 100 μL as recommended by the manufacturer (BRL). 1 μL of the reaction product was used to amplify overlapping regions of the cDNA that spanned the open reading frame. Primer pair used to identify the mutation R95X: (L) 5'-GAGCGCAGAGTGAGAACCAC-3' SEQ ID NO:16, (R) 5'-ACTGTATTCTGCAGAGCTGC-3' SEQ ID NO:17. PCR cycling conditions were: 94 C., 5 min, followed by 94 C., 45 sec; 60 C., 45 sec; 72 C., 45 sec; for 35 cycles, and extension at 72 C. for 5 min. 5 μL aliquots were run in 2% agarose gels. Heteroduplex analysis was performed as recommended by the manufacturer (MDE, AT Biochemicals). Heteroduplexes were visualized under UV light in the presence of ethidium bromide and photographed. Amplified cDNA fragments with altered mobility were subcloned into the TA vector according to the manufacturer's recommendations (Invitrogen). Sequence analysis were then performed using standard techniques.

Verification of the mutation

PCR reactions on genomic DNA (50 μg) were carried out using the upstream primer 5'-TTCCTTTCCCCTACCTTGTG-3' (SEQ ID NO:18) and the downstream printer 5'-TGTGGAAGCCTGGCAGACAT-3' (SEQ ID NO:19), which are located in the intron 2 and exon 3 of LAMC2 respectively. PCR conditions were: 95° C., 5 min, followed by 94° C., 45 sec; 56° C., 45 sec; 72° C., 45 sec; for 35 cycles, and extension at 72° C. for 5 min. PCR products were used for restriction analysis. 20 μL of PCR product obtained from genomic DNA was digested with TaqI for 2 hours (Boehringer Mannheim). Cleavage products were electrophoresed (2.4% agarose) stained and visualized under UV light.

›EXAMPLE 2 · 2 of 2

Thus the methods allow for the screening of patients for mutations in the γ2 chain which correlate with H-JEB. As demonstrated, the results have identified a nonsense mutation resulting in a truncated γ2 chain, leading to severe H-JEB. This was further confirmed by specific amplification and restriction enzyme analysis of both the patient and relatives. Thus demonstrating the effective screening for, and identification of, γ2 chain mutations which correlate with H-JEB. The methods are thus useful for diagnosis, prenatal screening, early screening and detection, as well as detailed examination of H-JEB. Furthermore, the results demonstrate the significance of the γ2 chain in forming proper cellular contacts.

›EXAMPLE 3 · 1 of 3

γ2 Chain as Diagnostic for Invasive

In this example, in situ hybridization is used to demonstrate the expression of the kalinin/laminin 5 γ2 chain in a variety of human cancer tissues and in skin wound healing in mice (Pyke et al., Amer. J. Pathol., Oct. 1994, 145(4):1-10 in press).

Thirty-six routinely processed, formalin-fixed and paraffin wax-embedded specimens from cancer surgery performed from 1991 to 1993 were drawn from pathology department files at Herlev Hospital (Copenhagen, Denmark). The specimens were evaluated according to standard criteria and included 16 cases of moderately or well-differentiated colon adenocarcinomas, 7 cases of ductal mammary carcinomas, 4 squamous cell carcinomas (2 skin, 1 cervix, 1 vulva), 3 malignant melanomas, and 6 sarcomas (3 leiomyosarcomas, 2 malignant fibrous histiocytomas, 1 neurofibrosarcoma).

All samples were selected upon histological examination of a hematoxylin and eosinstained section to ensure that they showed a well preserved morphology throughout and contained representative areas of both cancerous tissue and surrounding apparently normal, unaffected tissue. The broad zone separating these two tissue compartments is referred to as the invasive front in the following. No estimation of the effect of variations in fixation conditions was attempted, but in a previous study of plasminogen activating system components using specimens of colon adenocarcinomas collected using the same procedures, very little variation in relative mRNA levels was found (Pyke, C. PhD. Thesis, 1993, University of Copenhagen, Denmark). In addition, tissue from incisionally wounded mouse skin prepared as described by Romer et al. (J. Invest. Dermatol., 1994, 102:519-522), was fixed and paraffin-embedded the same way as the human cancer specimens.

For preparation of total RNA from six samples of colon adenocarcinomas, tissues were snap-frozen in liquid nitrogen immediately following resection and RNA was prepared as described by Lund et al., (Biochem. J., 1994, in press).

Probes:

Fragments of the cDNA for the γ2 chain of human kalinin/laminin 5 were inserted into RNA transcription vectors by restriction enzyme cutting of clone L15 covering base pairs 2995 to 3840 (FIG. 4; Kallunki et al., 1992, supra.). In brief, plasmids phb2t-01 and phb2t-02 were prepared by insertion of the complete L15 γ2 chain cDNA in sense and anti-sense orientation into the polylinker of plasmid vectors SP64 and SP65 (both Promega, Madison, Wis.), respectively. In addition, two non-overlapping fragments of clone L15 were bluntend cloned into the EcoRV-site of pKS(Bluescript)II(+) (Stratagene, La Jolla, Calif.) transcription vector and the resulting plasmids were verified by dideoxy sequencing according to Sanger et al. (PNAS(USA), 1977, 74:5463-5471). Plasmid phb2t-03 cover bases 3003-3239 and phb2t-05 cover bases 3239 to 3839, numbers referring to cDNA sequence Z15008 in the EMBL/GenBank/DDBJ database as reported by Kallunki et al., (1992, supra.; FIG. 4).

Similarly, cDNA fragments of other human laminin chains were prepared in RNA transcription vectors, yielding the following plasmid constructs (numbers in brackets refer to base pair numbers in the EMBL/GenBank/DDBJ sequence database by the listed accession numbers); chain α1: plasmid phae-01 (3244-3584 (accession No. X58531, Nissinen et al., Biochem. J., 1991, 276:369-379) in pKS(Bluescript)II(+)); chain β1: plasmid phb1e-01 (3460-4366 (accession No. J02778, Pikkarainen et al., J. Biol. Chem., 1987, 262:10454-10462) in pKS(Bluescript)II(+)); chain γ1: plasmids A1PSP64 and A1PSP65 (919-1535 (accession No. M55210, Pikkarainen et al., J. Biol. Chem., 1988, 263:6751-6758) in SP64 and SP65 repectively (sense and anti-sense orientation)).

All plasmids were linearized for transcription using restriction endonucleases and 5 μg of the linearized plasmids was extracted with phenol and with choloroform/isoamyl alcohol (25:1), precipitated with ethanol, and redissolved in water. Each transcription reaction contained 1 μg linearized DNA template, and transcriptions were performed essentially as recommended by the manufacturer of the polymerases. The RNA was hydrolyzed in 0.1 mol/L sodium carbonate buffer, pH 10.2, containing 10 mmol/L dithiothreitol (DTT) to an average size of 100 bases. RNA probes transcribed from opposite strands of the same plasmid template, yielding sense and anti-sense transcripts, were adjusted to ×10 6 cpm/μL and stored at -20° C. until used. Probes were applied to tissue sections.

In situ Hybridization:

In situ hybridization was performed as described by Pyke et al., (Am. J. Pathol., 1991, 38:1059-1067) with 35S labeled RNA probes prepared as described above. In brief, paraffin sections were cut, placed on gelatinized slides, heated to 60° C. for 30 minutes, deparaffinized in xylene, and rehydrated through graded alcohols to PBS (0.01 mol/L sodium phosphate buffer, pH 7.4, containing 0.14 mol/L NaCl). The slides were then washed twice in PBS, incubated with 5 μg/mL proteinase K in 50 mmol/L Tris/HCl, pH 8.0, with 5 mmol/L EDTA for 7.5 minutes, washed in PBS (2 minutes), dehydrated in graded ethanols, and air-dried before the RNA probe (˜80 pg/μL) was applied. The hybridization solution consisted of deionized formamide (50%), dextran sulfate (10%), tRNA (1 μg/μL), Ficoll 400 (0.02% (w/v)), polyvinylpyrrolidone (0.02% (w/v)), BSA fraction V (0.02% (w/v)), 10 mmol/L DTT, 0.3M NaCl, 0.5 mmol/L EDTA, 10 mmol/L Tris-HCl, and 10 mmol/L NaPO 4 (pH 6.8). Sections were covered by alcohol-washed, autoclaved coverslips and hybridized at 47° C. overnight (16 to 18 hours) in a chamber humidified with 10 ml of a mixture similar to the hybridization solution, except for the omission of probe, dextran sulfate, DTT, and tRNA (washing mixture). After hybridization, slides were washed in washing mixture for 2×1 hour at 50 C., followed by 0.5 mol/L NaCl, 1 mmol/L EDTA, 10 mmol/L Tris-HCl (pH 7.2) (NTE) with 10 mmol/L DTT at 37 C. for 15 minutes. After treatment with RNAse A (20 μg/mL) in NTE at 37 C. for 30 minutes, the sections were washed in NTE at 37 C. (2×30 minutes), and in 2 L of 15 mmol/L sodium chloride, 1.5 mmol/l sodium citrate, pH 7.0, with 1 mmol/L DTT for 30 minutes at room temperature with stirring. Sections were then dehydrated and air-dried. Finally, autoradiographic emulsion sec applied according to the manufacturer's reccomendations, and sections were stored in black airtight boxes at 4 C. until they were developed after 1 to 2 weeks of exposure.

›EXAMPLE 3 · 2 of 3

Results; Laminin α1, β1, γ1, and γ2 chains

All rounds of in situ hybridization include both sense and anti-sense RNA probes for each of the genes studied. As negative controls, sense RNA probes are applied to adjacent sections and these probes consistently are negative. As a positive control of the γ2 chain hybridizations, two anti-sense probes derived from non-overlapping γ2 chain cDNA clones are used on a number of sections. To summarizes the γ2 chain expression found; all carcinomas were positive except for one case of mammary duct carcinoma, and all three cases of leiomyosarcomas, both cases of malignant fibrous histiocytoma, and the only case of neurofibrosarcoma. The positive controls always give similar staining on adjacent sections (see FIG. 2, E and G). Fifteen of the malignant cases and all mouse tissue blocks were hybridized on two or more separate occasions giving the same hybridization pattern. All cell types other than those described below were negative in all cases.

Colon Adenocarcinoma

Sixteen specimens of colon adenocarcinoma were investigated by in situ hybridization for expression of the γ2 chain (FIG. 1). In all of these cases, mRNA for γ2 chain was present exclusively in cancer cells and in most of the cases, staining was confined to a distinct subpopulation of cancer cells at the invasive front (FIG. 1, A-D). A characteristic feature of γ2 chain containing cancer cells at the invasive front was that they appeared to represent cells in the process of branching or dissociating from larger well differentiated epithelial glands, a phenomenon referred to in the literature as tumor budding or tumor-cell dissociation.

In normal-looking colon mucosa distal from the invasive carcinoma, moderate signals for γ2 chain mRNA were observed in two specimens in the epithelial cells of a few mucosal glands that showed clear morphological signs of glandular disintegration and phagocytic cell infiltration. Apart from this, a weak signal was seen in luminal epithelial cells in normal looking colon mucosa in most specimens.

Weak signals for laminin chains α1, β1, and γ1 mRNAs were detected in cancerous areas of the 6 colon cancers studied for the expression of these genes. The expression of each of the three genes showed a similar distribution. Expression in stromal cells with a fibroblast-like morphology as well as in endothelial cells of smaller vessels was consistently found. In marked contrast to the γ2 chain expression in the same samples, expression of α1, β1, or γ1 was never found in cancer cells and no correlation between expression of α1, β1, and γ1 chains with sites of invasion was found. Adjacent normal-looking parts of the samples were negative or only weakly positive for these laminin chains.

FIG. 1 shows in situ hybridization of a specimen of colon adenocarcinoma for γ2 chain mRNA using a S-35 labeled anti-sense RNA probe derived from plasmid pbb2r-02. FIG. 1A is a cluster of heavily labeled cancer cells at the invasive front (open arrow) in close proximity to a well-differentiated glandular structure (straight arrow). FIG. 1B shows a high-magnification view of the area at the open arrow in 1A. Note that the isolated cancer cells show prominent labeling, whereas many coherent cancer cells of an adjacent glandular structure are negative (straight arrow). FIG. 1C shows the same pattern at an invasive focus in another part of the same specimen. FIG. 1D shows strong γ2 chain expression in cancer cells engaged in a bifurcation process (curved arrows). The malignant glandular epithelium from which the γ2 chain-positive cancer cells are branching is negative (straight arrow). Magnification:1A×100; 1B-1D×640.

Ductal Mammary Carcinomas

Six of the seven cases showed a prominent signal for γ2 chain in a small subpopulation of cells intimately associated with invasively growing malignant glandular structures. The most prominent signal was seen in cells located at the border between malignant and surrounding stromal tissue in glandular structures that exhibited clear histological signs of active invasion (FIG. 2A). On careful examination it was concluded that the majority of the positive cells were cancer cells but it was not possible to determine if the cells of myoepithelial origin were also positive in some cases. One case was totally negative. Normal-appearing glandular tissue was negative in all cases.

Weak signals for laminin chains α1, β1, and γ1 mRNAs were detected in fibroblast-like stromal cells throughout cancerous areas in one of the cases.

Malignant Melanoma

In all three cases strong hybridization of γ2 chain was found in a population of cancer cells in the radial growth phase (FIG. 2B). Laminin chains α1, β1, and γ1 were weakly expressed in the endothelium of small vessels and in fibroblast-like stromal cells throughout the affected areas in the two cases studied for these components. In addition, a weak signal for these chains was seen in sebaceous glands of adjacent normal skin.

Squamous Cell Carcinomas

In all four squamous cell carcinomas investigated, the same pattern of γ2 chain expression was found as in other carcinomas. The signals were found only in cancer cells, and only in areas with signs of ongoing invasion (FIG. 2, C-G).

The four cases were also studied for mRNA of α1, β1, and γ1 chains. In the two skin cancers, it was found that a very weak signal occurred in malignant cells, and that the weak signal was in all cancer cells and of an equal intensity. This is in clear contrast to the pattern of expression of the γ2 chain. As seen in melanomas, epithelial cells of sebaceous glands present in adjacent unaffected skin were weakly positive for these laminin chains. In the other two cases (cervix and vulva) weak expression of α1, β1, and γ1 chains were seen only in endothelial and fibroblast-like stromal cells throughout the cancerous areas (FIG. 2F).

FIG. 2 shows In situ hybridization for γ2 chain mRNA on sections of ductal mammary carcinoma (2A), malignant melanoma (2B), squamous cell carcinoma of the skin (2C-2D), and squamous cell carcinoma of the vulva (2E-2G). In 2A, cancer shows prominent signal for γ2 chain mRNA in cells bordering the zone between malignant glandular tissue and surrounding mesenchyme (curved arrows). Cancer cells located more centrally in individual malignant glandular structures are negative for γ2 chain mRNA (straight arrows). Note the wedge shaped form of the invading glandular tissue. (All images marked X' are darkfield images of the respective sections). FIG. 2B shows γ2 chain mRNA signal in a subpopulation of cancer cells of radially growing malignant epithelium (curved arrows). Adjacent malignant epithelium showing a different growth pattern is devoid a signal (straight arrow). FIG. 2C shows γ2 chain mRNA containing cancer cells at the invasive front (curved arrow). Note lack of signal in non-invasive areas of the tumor and in adjacent unaffected areas (straight arrow). FIG. 2D is a higher magnification of area of curved arrow of 2C highlighting the prominent signal in invading cells (curved arrow). Adjacent cancer cells with tumor islets are negative (straight arrow). FIG. 2E shows a strong signal for γ2 chain mRNA is seen in invading cancer cells, using an anti-sense RNA probe derived from plasmid pb2t-03 (curved arrow). A postcapillary venule is negative (straight arrow). FIG. 2F is a near adjacent section hybridized for laminin γ1 chain. Note that the endothelial cells of the venule show signal (straight arrow) whereas the malignant epithelium is negative (curved arrow). FIG. 2G is another near-adjacent section which was hybridized for γ2 chain expression using an anti-sense RNA probe derived from a cDNA plasmid non-overlapping with that used for preparing the probe in 2E (phb2t-05). Note that the hybridization pattern is similar to that seen in 2E, with strong signal in invading cancer cells (curved arrow) and absence of signal in a vessel (straight arrow). Magnification: 2C×100, all others ×640.

›EXAMPLE 3 · 3 of 3

Sarcomas

All six sarcomas tested in the study were totally negative for γ2 chain mRNA. The expression of other laminin chains was not tested.

Mouse Wounded Skin

To compare the gene expression of γ2 chain in cancer tissue with a nonmalignant condition known to contain actively migrating epithelial cells showing a transient invasive phenotype, we hybridized sections of incisionally wounded mouse skin with γ2 chain sense and anti-sense RNA probes. Weak γ2 chain expression was observed in the keratinocytes at the edge of 12-hour old wounds, and at later time points (1-5 days), strong signals for γ2 chain mRNA was seen exclusively in the basal keratinocytes of the epidermal tongue moving under the wound clot (FIG. 3). In adjacent normal-looking skin, keratinocytes were negative for γ2 chain mRNA.

FIG. 3 is incisionally wounded mouse skin (γ2 hours after wounding) showing signal for γ2 chain in keratinocytes at the leading edge of the migrating epithelium (curved arrow). Whereas buccal keratinocytes located more distant to the site of injury show little or no signal (straight arrow). Note that the signal for γ2 chain stops at the tip of invading keratinocytes (open arrow). A' is a dark field image of 3A. Magnification: ×640.

RNAse Protection Assay

Plasmid phbt-03 was linearized with EcoRI and a radiolabeled RNA-anti-sense probe was prepared by transcription using 32 P UTP and T3 polymerase (Pyke et al., FEBS Letters, 1993, 326:69-75). RNAse protection assay, using 40 μg ethanol-precipitated and DNAse I-treated total RNA from six samples of colon adenocarcinomas was performed as described in Pyke et al., (1993, supra.). Protected mRNA regions were analyzed on a denaturing polyacrylamide gel and autoradiography.

The RNAse protection assay carried out on total RNA from the six samples confirmed the presence of genuine γ2 chain mRNA in all samples.

These results clearly demonstrate the important correlation of γ2 chain expression and invasive cell phenotype in vivo, as detected in vitro. Thus the instant methods present a novel and important method for the specific identification of invasive cell phenotypes in biopsied tissues. The knowledge of any information diagnostic for the presence or absence of invasive cells is useful for the monitoring and prognosis of continuing anti-carcinoma therapies. Further the identification of the expression or non-expression of the γ2 chain provides important information as to the phenotypic nature of the tissue examined. Thus the instant example demonstrates the use of probes of γ2 chain for detection of the presence, or absence, of invasive cells.

Those skilled in the art will know, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. These and all other equivalents are intended to be encompassed by the following claims.

__________________________________________________________________________

›SEQUENCE LISTING

(1) GENERAL INFORMATION:

(iii) NUMBER OF SEQUENCES: 19

(2) INFORMATION FOR SEQ ID NO:1:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligomer primers"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGCTCACCAAGACTTACACA20

(2) INFORMATION FOR SEQ ID NO:2:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GAATCACTGAGCAGCTGAAC20

(2) INFORMATION FOR SEQ ID NO:3:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CAGTACCAGAACCGAGTTCG20

(2) INFORMATION FOR SEQ ID NO:4:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CTGGTTACCAGGCTTGAGAG20

(2) INFORMATION FOR SEQ ID NO:5:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTACTGCGGAATCTCACAGC20

(2) INFORMATION FOR SEQ ID NO:6:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TACACTGTTCAACCCAGGGT20

(2) INFORMATION FOR SEQ ID NO:7:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAACAAGCCCTCTCACTGGT20

(2) INFORMATION FOR SEQ ID NO:8:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCGGAGACTGTGCTGATAAG20

(2) INFORMATION FOR SEQ ID NO:9:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CATACCTCTCTACATGGCAT20

(2) INFORMATION FOR SEQ ID NO:10:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AGTCTCGCTGAATCTCTCTT20

(2) INFORMATION FOR SEQ ID NO:11:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TTACAACTAGCATGGTGCCC20

(2) INFORMATION FOR SEQ ID NO:12:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 5200 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: sig.sub.-- peptide

(B) LOCATION: 118..183

(ix) FEATURE:

›(A) NAME/KEY: CDS · 1 of 2

(B) LOCATION: 118..3699

(ix) FEATURE:

(A) NAME/KEY: polyA.sub.-- site

(B) LOCATION: 4433

(ix) FEATURE:

(A) NAME/KEY: polyA.sub.-- site

(B) LOCATION: 5195

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GACCACCTGATCGAAGGAAAAGGAAGGCACAGCGGAGCGCAGAGTGAGAACCACCAACCG60

AGGCGCCGGGCAGCGACCCCTGCAGCGGAGACAGAGACTGAGCGGCCCGGCACCGCC117

ATGCCTGCGCTCTGGCTGGGCTGCTGCCTCTGCTTCTCGCTCCTCCTG165

MetProAlaLeuTrpLeuGlyCysCysLeuCysPheSerLeuLeuLeu

151015

CCCGCAGCCCGGGCCACCTCCAGGAGGGAAGTCTGTGATTGCAATGGG213

ProAlaAlaArgAlaThrSerArgArgGluValCysAspCysAsnGly

202530

AAGTCCAGGCAGTGTATCTTTGATCGGGAACTTCACAGACAAACTGGT261

LysSerArgGlnCysIlePheAspArgGluLeuHisArgGlnThrGly

354045

AATGGATTCCGCTGCCTCAACTGCAATGACAACACTGATGGCATTCAC309

AsnGlyPheArgCysLeuAsnCysAsnAspAsnThrAspGlyIleHis

505560

TGCGAGAAGTGCAAGAATGGCTTTTACCGGCACAGAGAAAGGGACCGC357

CysGluLysCysLysAsnGlyPheTyrArgHisArgGluArgAspArg

65707580

TGTTTGCCCTGCAATTGTAACTCCAAAGGTTCTCTTAGTGCTCGATGT405

CysLeuProCysAsnCysAsnSerLysGlySerLeuSerAlaArgCys

859095

GACAACTCTGGACGGTGCAGCTGTAAACCAGGTGTGACAGGAGCCAGA453

AspAsnSerGlyArgCysSerCysLysProGlyValThrGlyAlaArg

100105110

TGCGACCGATGTCTGCCAGGCTTCCACATGCTCACGGATGCGGGGTGC501

CysAspArgCysLeuProGlyPheHisMetLeuThrAspAlaGlyCys

115120125

ACCCAAGACCAGAGACTGCTAGACTCCAAGTGTGACTGTGACCCAGCT549

ThrGlnAspGlnArgLeuLeuAspSerLysCysAspCysAspProAla

130135140

GGCATCGCAGGGCCCTGTGACGCGGGCCGCTGTGTCTGCAAGCCAGCT597

GlyIleAlaGlyProCysAspAlaGlyArgCysValCysLysProAla

145150155160

GTTACTGGAGAACGCTGTGATAGGTGTCGATCAGGTTACTATAATCTG645

ValThrGlyGluArgCysAspArgCysArgSerGlyTyrTyrAsnLeu

165170175

GATGGGGGGAACCCTGAGGGCTGTACCCAGTGTTTCTGCTATGGGCAT693

AspGlyGlyAsnProGluGlyCysThrGlnCysPheCysTyrGlyHis

180185190

TCAGCCAGCTGCCGCAGCTCTGCAGAATACAGTGTCCATAAGATCACC741

SerAlaSerCysArgSerSerAlaGluTyrSerValHisLysIleThr

195200205

TCTACCTTTCATCAAGATGTTGATGGCTGGAAGGCTGTCCAACGAAAT789

SerThrPheHisGlnAspValAspGlyTrpLysAlaValGlnArgAsn

210215220

GGGTCTCCTGCAAAGCTCCAATGGTCACAGCGCCATCAAGATGTGTTT837

GlySerProAlaLysLeuGlnTrpSerGlnArgHisGlnAspValPhe

225230235240

AGCTCAGCCCAACGACTAGATCCTGTCTATTTTGTGGCTCCTGCCAAA885

SerSerAlaGlnArgLeuAspProValTyrPheValAlaProAlaLys

245250255

TTTCTTGGGAATCAACAGGTGAGCTATGGGCAAAGCCTGTCCTTTGAC933

PheLeuGlyAsnGlnGlnValSerTyrGlyGlnSerLeuSerPheAsp

260265270

TACCGTGTGGACAGAGGAGGCAGACACCCATCTGCCCATGATGTGATC981

TyrArgValAspArgGlyGlyArgHisProSerAlaHisAspValIle

275280285

CTGGAAGGTGCTGGTCTACGGATCACAGCTCCCTTGATGCCACTTGGC1029

LeuGluGlyAlaGlyLeuArgIleThrAlaProLeuMetProLeuGly

290295300

AAGACACTGCCTTGTGGGCTCACCAAGACTTACACATTCAGGTTAAAT1077

LysThrLeuProCysGlyLeuThrLysThrTyrThrPheArgLeuAsn

305310315320

GAGCATCCAAGCAATAATTGGAGCCCCCAGCTGAGTTACTTTGAGTAT1125

GluHisProSerAsnAsnTrpSerProGlnLeuSerTyrPheGluTyr

325330335

CGAAGGTTACTGCGGAATCTCACAGCCCTCCGCATCCGAGCTACATAT1173

ArgArgLeuLeuArgAsnLeuThrAlaLeuArgIleArgAlaThrTyr

340345350

GGAGAATACAGTACTGGGTACATTGACAATGTGACCCTGATTTCAGCC1221

GlyGluTyrSerThrGlyTyrIleAspAsnValThrLeuIleSerAla

355360365

CGCCCTGTCTCTGGAGCCCCAGCACCCTGGGTTGAACAGTGTATATGT1269

ArgProValSerGlyAlaProAlaProTrpValGluGlnCysIleCys

370375380

CCTGTTGGGTACAAGGGGCAATTCTGCCAGGATTGTGCTTCTGGCTAC1317

ProValGlyTyrLysGlyGlnPheCysGlnAspCysAlaSerGlyTyr

385390395400

AAGAGAGATTCAGCGAGACTGGGGCCTTTTGGCACCTGTATTCCTTGT1365

LysArgAspSerAlaArgLeuGlyProPheGlyThrCysIleProCys

405410415

AACTGTCAAGGGGGAGGGGCCTGTGATCCAGACACAGGAGATTGTTAT1413

AsnCysGlnGlyGlyGlyAlaCysAspProAspThrGlyAspCysTyr

420425430

TCAGGGGATGAGAATCCTGACATTGAGTGTGCTGACTGCCCAATTGGT1461

SerGlyAspGluAsnProAspIleGluCysAlaAspCysProIleGly

435440445

TTCTACAACGATCCGCACGACCCCCGCAGCTGCAAGCCATGTCCCTGT1509

PheTyrAsnAspProHisAspProArgSerCysLysProCysProCys

450455460

CATAACGGGTTCAGCTGCTCAGTGATTCCGGAGACGGAGGAGGTGGTG1557

HisAsnGlyPheSerCysSerValIleProGluThrGluGluValVal

465470475480

TGCAATAACTGCCCTCCCGGGGTCACCGGTGCCCGCTGTGAGCTCTGT1605

CysAsnAsnCysProProGlyValThrGlyAlaArgCysGluLeuCys

485490495

GCTGATGGCTACTTTGGGGACCCCTTTGGTGAACATGGCCCAGTGAGG1653

AlaAspGlyTyrPheGlyAspProPheGlyGluHisGlyProValArg

500505510

CCTTGTCAGCCCTGTCAATGCAACAGCAATGTGGACCCCAGTGCCTCT1701

ProCysGlnProCysGlnCysAsnSerAsnValAspProSerAlaSer

515520525

GGGAATTGTGACCGGCTGACAGGCAGGTGTTTGAAGTGTATCCACAAC1749

GlyAsnCysAspArgLeuThrGlyArgCysLeuLysCysIleHisAsn

530535540

ACAGCCGGCATCTACTGCGACCAGTGCAAAGCAGGCTACTTCGGGGAC1797

ThrAlaGlyIleTyrCysAspGlnCysLysAlaGlyTyrPheGlyAsp

545550555560

CCATTGGCTCCCAACCCAGCAGACAAGTGTCGAGCTTGCAACTGTAAC1845

ProLeuAlaProAsnProAlaAspLysCysArgAlaCysAsnCysAsn

565570575

CCCATGGGCTCAGAGCCTGTAGGATGTCGAAGTGATGGCACCTGTGTT1893

ProMetGlySerGluProValGlyCysArgSerAspGlyThrCysVal

580585590

TGCAAGCCAGGATTTGGTGGCCCCAACTGTGAGCATGGAGCATTCAGC1941

CysLysProGlyPheGlyGlyProAsnCysGluHisGlyAlaPheSer

595600605

TGTCCAGCTTGCTATAATCAAGTGAAGATTCAGATGGATCAGTTTATG1989

CysProAlaCysTyrAsnGlnValLysIleGlnMetAspGlnPheMet

610615620

CAGCAGCTTCAGAGAATGGAGGCCCTGATTTCAAAGGCTCAGGGTGGT2037

GlnGlnLeuGlnArgMetGluAlaLeuIleSerLysAlaGlnGlyGly

625630635640

GATGGAGTAGTACCTGATACAGAGCTGGAAGGCAGGATGCAGCAGGCT2085

AspGlyValValProAspThrGluLeuGluGlyArgMetGlnGlnAla

645650655

GAGCAGGCCCTTCAGGACATTCTGAGAGATGCCCAGATTTCAGAAGGT2133

GluGlnAlaLeuGlnAspIleLeuArgAspAlaGlnIleSerGluGly

660665670

GCTAGCAGATCCCTTGGTCTCCAGTTGGCCAAGGTGAGGAGCCAAGAG2181

AlaSerArgSerLeuGlyLeuGlnLeuAlaLysValArgSerGlnGlu

675680685

AACAGCTACCAGAGCCGCCTGGATGACCTCAAGATGACTGTGGAAAGA2229

AsnSerTyrGlnSerArgLeuAspAspLeuLysMetThrValGluArg

690695700

GTTCGGGCTCTGGGAAGTCAGTACCAGAACCGAGTTCGGGATACTCAC2277

ValArgAlaLeuGlySerGlnTyrGlnAsnArgValArgAspThrHis

705710715720

AGGCTCATCACTCAGATGCAGCTGAGCCTGGCAGAAAGTGAAGCTTCC2325

ArgLeuIleThrGlnMetGlnLeuSerLeuAlaGluSerGluAlaSer

725730735

TTGGGAAACACTAACATTCCTGCCTCAGACCACTACGTGGGGCCAAAT2373

LeuGlyAsnThrAsnIleProAlaSerAspHisTyrValGlyProAsn

740745750

GGCTTTAAAAGTCTGGCTCAGGAGGCCACAAGATTAGCAGAAAGCCAC2421

GlyPheLysSerLeuAlaGlnGluAlaThrArgLeuAlaGluSerHis

755760765

GTTGAGTCAGCCAGTAACATGGAGCAACTGACAAGGGAAACTGAGGAC2469

ValGluSerAlaSerAsnMetGluGlnLeuThrArgGluThrGluAsp

770775780

TATTCCAAACAAGCCCTCTCACTGGTGCGCAAGGCCCTGCATGAAGGA2517

TyrSerLysGlnAlaLeuSerLeuValArgLysAlaLeuHisGluGly

785790795800

GTCGGAAGCGGAAGCGGTAGCCCGGACGGTGCTGTGGTGCAAGGGCTT2565

ValGlySerGlySerGlySerProAspGlyAlaValValGlnGlyLeu

805810815

GTGGAAAAATTGGAGAAAACCAAGTCCCTGGCCCAGCAGTTGACAAGG2613

ValGluLysLeuGluLysThrLysSerLeuAlaGlnGlnLeuThrArg

820825830

GAGGCCACTCAAGCGGAAATTGAAGCAGATAGGTCTTATCAGCACAGT2661

›(A) NAME/KEY: CDS · 2 of 2

GluAlaThrGlnAlaGluIleGluAlaAspArgSerTyrGlnHisSer

835840845

CTCCGCCTCCTGGATTCAGTGTCTCCGCTTCAGGGAGTCAGTGATCAG2709

LeuArgLeuLeuAspSerValSerProLeuGlnGlyValSerAspGln

850855860

TCCTTTCAGGTGGAAGAAGCAAAGAGGATCAAACAAAAAGCGGATTCA2757

SerPheGlnValGluGluAlaLysArgIleLysGlnLysAlaAspSer

865870875880

CTCTCAAGCCTGGTAACCAGGCATATGGATGAGTTCAAGCGTACACAA2805

LeuSerSerLeuValThrArgHisMetAspGluPheLysArgThrGln

885890895

AAGAATCTGGGAAACTGGAAAGAAGAAGCACAGCAGCTCTTACAGAAT2853

LysAsnLeuGlyAsnTrpLysGluGluAlaGlnGlnLeuLeuGlnAsn

900905910

GGAAAAAGTGGGAGAGAGAAATCAGATCAGCTGCTTTCCCGTGCCAAT2901

GlyLysSerGlyArgGluLysSerAspGlnLeuLeuSerArgAlaAsn

915920925

CTTGCTAAAAGCAGAGCACAAGAAGCACTGAGTATGGGCAATGCCACT2949

LeuAlaLysSerArgAlaGlnGluAlaLeuSerMetGlyAsnAlaThr

930935940

TTTTATGAAGTTGAGAGCATCCTTAAAAACCTCAGAGAGTTTGACCTG2997

PheTyrGluValGluSerIleLeuLysAsnLeuArgGluPheAspLeu

945950955960

CAGGTGGACAACAGAAAAGCAGAAGCTGAAGAAGCCATGAAGAGACTC3045

GlnValAspAsnArgLysAlaGluAlaGluGluAlaMetLysArgLeu

965970975

TCCTACATCAGCCAGAAGGTTTCAGATGCCAGTGACAAGACCCAGCAA3093

SerTyrIleSerGlnLysValSerAspAlaSerAspLysThrGlnGln

980985990

GCAGAAAGAGCCCTGGGGAGCGCTGCTGCTGATGCACAGAGGGCAAAG3141

AlaGluArgAlaLeuGlySerAlaAlaAlaAspAlaGlnArgAlaLys

99510001005

AATGGGGCCGGGGAGGCCCTGGAAATCTCCAGTGAGATTGAACAGGAG3189

AsnGlyAlaGlyGluAlaLeuGluIleSerSerGluIleGluGlnGlu

101010151020

ATTGGGAGTCTGAACTTGGAAGCCAATGTGACAGCAGATGGAGCCTTG3237

IleGlySerLeuAsnLeuGluAlaAsnValThrAlaAspGlyAlaLeu

1025103010351040

GCCATGGAAAAGGGACTGGCCTCTCTGAAGAGTGAGATGAGGGAAGTG3285

AlaMetGluLysGlyLeuAlaSerLeuLysSerGluMetArgGluVal

104510501055

GAAGGAGAGCTGGAAAGGAAGGAGCTGGAGTTTGACACGAATATGGAT3333

GluGlyGluLeuGluArgLysGluLeuGluPheAspThrAsnMetAsp

106010651070

GCAGTACAGATGGTGATTACAGAAGCCCAGAAGGTTGATACCAGAGCC3381

AlaValGlnMetValIleThrGluAlaGlnLysValAspThrArgAla

107510801085

AAGAACGCTGGGGTTACAATCCAAGACACACTCAACACATTAGACGGC3429

LysAsnAlaGlyValThrIleGlnAspThrLeuAsnThrLeuAspGly

109010951100

CTCCTGCATCTGATGGACCAGCCTCTCAGTGTAGATGAAGAGGGGCTG3477

LeuLeuHisLeuMetAspGlnProLeuSerValAspGluGluGlyLeu

1105111011151120

GTCTTACTGGAGCAGAAGCTTTCCCGAGCCAAGACCCAGATCAACAGC3525

ValLeuLeuGluGlnLysLeuSerArgAlaLysThrGlnIleAsnSer

112511301135

CAACTGCGGCCCATGATGTCAGAGCTGGAAGAGAGGGCACGTCAGCAG3573

GlnLeuArgProMetMetSerGluLeuGluGluArgAlaArgGlnGln

114011451150

AGGGGCCACCTCCATTTGCTGGAGACAAGCATAGATGGGATTCTGGCT3621

ArgGlyHisLeuHisLeuLeuGluThrSerIleAspGlyIleLeuAla

115511601165

GATGTGAAGAACTTGGAGAACATTAGGGACAACCTGCCCCCAGGCTGC3669

AspValLysAsnLeuGluAsnIleArgAspAsnLeuProProGlyCys

117011751180

TACAATACCCAGGCTCTTGAGCAACAGTGAAGCTGCCATAAATATTTCTC3719

TyrAsnThrGlnAlaLeuGluGlnGln*

11851190

AACTGAGGTTCTTGGGATACAGATCTCAGGGCTCGGGAGCCATGTCATGTGAGTGGGTGG3779

GATGGGGACATTTGAACATGTTTAATGGGTATGCTCAGGTCAACTGACCTGACCCCATTC3839

CTGATCCCATGGCCAGGTGGTTGTCTTATTGCACCATACTCCTTGCTTCCTGATGCTGGG3899

CATGAGGCAGATAGGCACTGGTGTGAGAATGATCAAGGATCTGGACCCCAAAGATAGACT3959

GGATGGAAAGACAAACTGCACAGGCAGATGTTTGCCTCATAATAGTCGTAAGTGGAGTCC4019

TGGAATTTGGACAAGTGCTGTTGGGATATAGTCAACTTATTCTTTGAGTAATGTGACTAA4079

AGGAAAAAACTTTGACTTTGCCCAGGCATGAAATTCTTCCTAATGTCAGAACAGAGTGCA4139

ACCCAGTCACACTGTGGCCAGTAAAATACTATTGCCTCATATTGTCCTCTGCAAGCTTCT4199

TGCTGATCAGAGTTCCTCCTACTTACAACCCAGGGTGTGAACATGTTCTCCATTTTCAAG4259

CTGGAAGAAGTGAGCAGTGTTGGAGTGAGGACCTGTAAGGCAGGCCCATTCAGAGCTATG4319

GTGCTTGCTGGTGCCTGCCACCTTCAAGTTCTGGACCTGGGCATGACATCCTTTCTTTTA4379

ATGATGCCATGGCAACTTAGAGATTGCATTTTTATTAAAGCATTTCCTACCAGCAAAGCA4439

AATGTTGGGAAAGTATTTACTTTTTCGGTTTCAAAGTGATAGAAAAGTGTGGCTTGGGCA4499

TTGAAAGAGGTAAAATTCTCTAGATTTATTAGTCCTAATTCAATCCTACTTTTCGAACAC4559

CAAAAATGATGCGCATCAATGTATTTTATCTTATTTTCTCAATCTCCTCTCTCTTTCCTC4619

CACCCATAATAAGAGAATGTTCCTACTCACACTTCAGCTGGGTCACATCCATCCCTCCAT4679

TCATCCTTCCATCCATCTTTCCATCCATTACCTCCATCCATCCTTCCAACATATATTTAT4739

TGAGTACCTACTGTGTGCCAGGGGCTGGTGGGACAGTGGTGACATAGTCTCTGCCCTCAT4799

AGAGTTGATTGTCTAGTGAGGAAGACAAGCATTTTTAAAAAATAAATTTAAACTTACAAA4859

CTTTGTTTGTCACAAGTGGTGTTTATTGCAATAACCGCTTGGTTTGCAACCTCTTTGCTC4919

AACAGAACATATGTTGCAAGACCCTCCCATGGGCACTGAGTTTGGCAAGGATGACAGAGC4979

TCTGGGTTGTGCACATTTCTTTGCATTCCAGCGTCACTCTGTGCCTTCTACAACTGATTG5039

CAACAGACTGTTGAGTTATGATAACACCAGTGGGAATTGCTGGAGGAACCAGAGGCACTT5099

CCACCTTGGCTGGGAAGACTATGGTGCTGCCTTGCTTCTGTATTTCCTTGGATTTTCCTG5159

AAAGTGTTTTTAAATAAAGAACAATTGTTAGATGCCAAAAA5200

(2) INFORMATION FOR SEQ ID NO:13:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 1193 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

MetProAlaLeuTrpLeuGlyCysCysLeuCysPheSerLeuLeuLeu

151015

ProAlaAlaArgAlaThrSerArgArgGluValCysAspCysAsnGly

202530

LysSerArgGlnCysIlePheAspArgGluLeuHisArgGlnThrGly

354045

AsnGlyPheArgCysLeuAsnCysAsnAspAsnThrAspGlyIleHis

505560

CysGluLysCysLysAsnGlyPheTyrArgHisArgGluArgAspArg

65707580

CysLeuProCysAsnCysAsnSerLysGlySerLeuSerAlaArgCys

859095

AspAsnSerGlyArgCysSerCysLysProGlyValThrGlyAlaArg

100105110

CysAspArgCysLeuProGlyPheHisMetLeuThrAspAlaGlyCys

115120125

ThrGlnAspGlnArgLeuLeuAspSerLysCysAspCysAspProAla

130135140

GlyIleAlaGlyProCysAspAlaGlyArgCysValCysLysProAla

145150155160

ValThrGlyGluArgCysAspArgCysArgSerGlyTyrTyrAsnLeu

165170175

AspGlyGlyAsnProGluGlyCysThrGlnCysPheCysTyrGlyHis

180185190

SerAlaSerCysArgSerSerAlaGluTyrSerValHisLysIleThr

195200205

SerThrPheHisGlnAspValAspGlyTrpLysAlaValGlnArgAsn

210215220

GlySerProAlaLysLeuGlnTrpSerGlnArgHisGlnAspValPhe

225230235240

SerSerAlaGlnArgLeuAspProValTyrPheValAlaProAlaLys

245250255

PheLeuGlyAsnGlnGlnValSerTyrGlyGlnSerLeuSerPheAsp

260265270

TyrArgValAspArgGlyGlyArgHisProSerAlaHisAspValIle

275280285

LeuGluGlyAlaGlyLeuArgIleThrAlaProLeuMetProLeuGly

290295300

LysThrLeuProCysGlyLeuThrLysThrTyrThrPheArgLeuAsn

305310315320

GluHisProSerAsnAsnTrpSerProGlnLeuSerTyrPheGluTyr

325330335

ArgArgLeuLeuArgAsnLeuThrAlaLeuArgIleArgAlaThrTyr

340345350

GlyGluTyrSerThrGlyTyrIleAspAsnValThrLeuIleSerAla

355360365

ArgProValSerGlyAlaProAlaProTrpValGluGlnCysIleCys

370375380

ProValGlyTyrLysGlyGlnPheCysGlnAspCysAlaSerGlyTyr

385390395400

LysArgAspSerAlaArgLeuGlyProPheGlyThrCysIleProCys

405410415

AsnCysGlnGlyGlyGlyAlaCysAspProAspThrGlyAspCysTyr

420425430

SerGlyAspGluAsnProAspIleGluCysAlaAspCysProIleGly

435440445

PheTyrAsnAspProHisAspProArgSerCysLysProCysProCys

450455460

HisAsnGlyPheSerCysSerValIleProGluThrGluGluValVal

465470475480

CysAsnAsnCysProProGlyValThrGlyAlaArgCysGluLeuCys

485490495

AlaAspGlyTyrPheGlyAspProPheGlyGluHisGlyProValArg

500505510

ProCysGlnProCysGlnCysAsnSerAsnValAspProSerAlaSer

515520525

GlyAsnCysAspArgLeuThrGlyArgCysLeuLysCysIleHisAsn

530535540

ThrAlaGlyIleTyrCysAspGlnCysLysAlaGlyTyrPheGlyAsp

545550555560

ProLeuAlaProAsnProAlaAspLysCysArgAlaCysAsnCysAsn

565570575

ProMetGlySerGluProValGlyCysArgSerAspGlyThrCysVal

580585590

CysLysProGlyPheGlyGlyProAsnCysGluHisGlyAlaPheSer

595600605

CysProAlaCysTyrAsnGlnValLysIleGlnMetAspGlnPheMet

610615620

GlnGlnLeuGlnArgMetGluAlaLeuIleSerLysAlaGlnGlyGly

625630635640

AspGlyValValProAspThrGluLeuGluGlyArgMetGlnGlnAla

645650655

GluGlnAlaLeuGlnAspIleLeuArgAspAlaGlnIleSerGluGly

660665670

AlaSerArgSerLeuGlyLeuGlnLeuAlaLysValArgSerGlnGlu

675680685

AsnSerTyrGlnSerArgLeuAspAspLeuLysMetThrValGluArg

690695700

ValArgAlaLeuGlySerGlnTyrGlnAsnArgValArgAspThrHis

705710715720

ArgLeuIleThrGlnMetGlnLeuSerLeuAlaGluSerGluAlaSer

725730735

LeuGlyAsnThrAsnIleProAlaSerAspHisTyrValGlyProAsn

740745750

GlyPheLysSerLeuAlaGlnGluAlaThrArgLeuAlaGluSerHis

755760765

ValGluSerAlaSerAsnMetGluGlnLeuThrArgGluThrGluAsp

770775780

TyrSerLysGlnAlaLeuSerLeuValArgLysAlaLeuHisGluGly

785790795800

ValGlySerGlySerGlySerProAspGlyAlaValValGlnGlyLeu

805810815

ValGluLysLeuGluLysThrLysSerLeuAlaGlnGlnLeuThrArg

820825830

GluAlaThrGlnAlaGluIleGluAlaAspArgSerTyrGlnHisSer

835840845

LeuArgLeuLeuAspSerValSerProLeuGlnGlyValSerAspGln

850855860

SerPheGlnValGluGluAlaLysArgIleLysGlnLysAlaAspSer

865870875880

LeuSerSerLeuValThrArgHisMetAspGluPheLysArgThrGln

885890895

LysAsnLeuGlyAsnTrpLysGluGluAlaGlnGlnLeuLeuGlnAsn

900905910

GlyLysSerGlyArgGluLysSerAspGlnLeuLeuSerArgAlaAsn

915920925

LeuAlaLysSerArgAlaGlnGluAlaLeuSerMetGlyAsnAlaThr

930935940

PheTyrGluValGluSerIleLeuLysAsnLeuArgGluPheAspLeu

945950955960

GlnValAspAsnArgLysAlaGluAlaGluGluAlaMetLysArgLeu

965970975

SerTyrIleSerGlnLysValSerAspAlaSerAspLysThrGlnGln

980985990

AlaGluArgAlaLeuGlySerAlaAlaAlaAspAlaGlnArgAlaLys

99510001005

AsnGlyAlaGlyGluAlaLeuGluIleSerSerGluIleGluGlnGlu

101010151020

IleGlySerLeuAsnLeuGluAlaAsnValThrAlaAspGlyAlaLeu

1025103010351040

AlaMetGluLysGlyLeuAlaSerLeuLysSerGluMetArgGluVal

104510501055

GluGlyGluLeuGluArgLysGluLeuGluPheAspThrAsnMetAsp

106010651070

AlaValGlnMetValIleThrGluAlaGlnLysValAspThrArgAla

107510801085

LysAsnAlaGlyValThrIleGlnAspThrLeuAsnThrLeuAspGly

109010951100

LeuLeuHisLeuMetAspGlnProLeuSerValAspGluGluGlyLeu

1105111011151120

ValLeuLeuGluGlnLysLeuSerArgAlaLysThrGlnIleAsnSer

112511301135

GlnLeuArgProMetMetSerGluLeuGluGluArgAlaArgGlnGln

114011451150

ArgGlyHisLeuHisLeuLeuGluThrSerIleAspGlyIleLeuAla

115511601165

AspValLysAsnLeuGluAsnIleArgAspAsnLeuProProGlyCys

117011751180

TyrAsnThrGlnAlaLeuGluGlnGln

11851190

(2) INFORMATION FOR SEQ ID NO:14:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 4316 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: sig.sub.-- peptide

(B) LOCATION: 118..183

(ix) FEATURE:

›(A) NAME/KEY: CDS · 1 of 2

(B) LOCATION: 118..3453

(ix) FEATURE:

(A) NAME/KEY: repeat.sub.-- unit

(B) LOCATION: 4021..4316

(D) OTHER INFORMATION: /rpt.sub.-- type="other"

/rpt.sub.-- family= "HUMAN ALU"

(ix) FEATURE:

(A) NAME/KEY: polyA.sub.-- site

(B) LOCATION: 4296

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GACCACCTGATCGAAGGAAAAGGAAGGCACAGCGGAGCGCAGAGTGAGAACCACCAACCG60

AGGCGCCGGGCAGCGACCCCTGCAGCGGAGACAGAGACTGAGCGGCCCGGCACCGCC117

ATGCCTGCGCTCTGGCTGGGCTGCTGCCTCTGCTTCTCGCTCCTCCTG165

MetProAlaLeuTrpLeuGlyCysCysLeuCysPheSerLeuLeuLeu

1195120012051210

CCCGCAGCCCGGGCCACCTCCAGGAGGGAAGTCTGTGATTGCAATGGG213

ProAlaAlaArgAlaThrSerArgArgGluValCysAspCysAsnGly

121512201225

AAGTCCAGGCAGTGTATCTTTGATCGGGAACTTCACAGACAAACTGGT261

LysSerArgGlnCysIlePheAspArgGluLeuHisArgGlnThrGly

123012351240

AATGGATTCCGCTGCCTCAACTGCAATGACAACACTGATGGCATTCAC309

AsnGlyPheArgCysLeuAsnCysAsnAspAsnThrAspGlyIleHis

124512501255

TGCGAGAAGTGCAAGAATGGCTTTTACCGGCACAGAGAAAGGGACCGC357

CysGluLysCysLysAsnGlyPheTyrArgHisArgGluArgAspArg

126012651270

TGTTTGCCCTGCAATTGTAACTCCAAAGGTTCTCTTAGTGCTCGATGT405

CysLeuProCysAsnCysAsnSerLysGlySerLeuSerAlaArgCys

1275128012851290

GACAACTCTGGACGGTGCAGCTGTAAACCAGGTGTGACAGGAGCCAGA453

AspAsnSerGlyArgCysSerCysLysProGlyValThrGlyAlaArg

129513001305

TGCGACCGATGTCTGCCAGGCTTCCACATGCTCACGGATGCGGGGTGC501

CysAspArgCysLeuProGlyPheHisMetLeuThrAspAlaGlyCys

131013151320

ACCCAAGACCAGAGACTGCTAGACTCCAAGTGTGACTGTGACCCAGCT549

ThrGlnAspGlnArgLeuLeuAspSerLysCysAspCysAspProAla

132513301335

GGCATCGCAGGGCCCTGTGACGCGGGCCGCTGTGTCTGCAAGCCAGCT597

GlyIleAlaGlyProCysAspAlaGlyArgCysValCysLysProAla

134013451350

GTTACTGGAGAACGCTGTGATAGGTGTCGATCAGGTTACTATAATCTG645

ValThrGlyGluArgCysAspArgCysArgSerGlyTyrTyrAsnLeu

1355136013651370

GATGGGGGGAACCCTGAGGGCTGTACCCAGTGTTTCTGCTATGGGCAT693

AspGlyGlyAsnProGluGlyCysThrGlnCysPheCysTyrGlyHis

137513801385

TCAGCCAGCTGCCGCAGCTCTGCAGAATACAGTGTCCATAAGATCACC741

SerAlaSerCysArgSerSerAlaGluTyrSerValHisLysIleThr

139013951400

TCTACCTTTCATCAAGATGTTGATGGCTGGAAGGCTGTCCAACGAAAT789

SerThrPheHisGlnAspValAspGlyTrpLysAlaValGlnArgAsn

140514101415

GGGTCTCCTGCAAAGCTCCAATGGTCACAGCGCCATCAAGATGTGTTT837

GlySerProAlaLysLeuGlnTrpSerGlnArgHisGlnAspValPhe

142014251430

AGCTCAGCCCAACGACTAGATCCTGTCTATTTTGTGGCTCCTGCCAAA885

SerSerAlaGlnArgLeuAspProValTyrPheValAlaProAlaLys

1435144014451450

TTTCTTGGGAATCAACAGGTGAGCTATGGGCAAAGCCTGTCCTTTGAC933

PheLeuGlyAsnGlnGlnValSerTyrGlyGlnSerLeuSerPheAsp

145514601465

TACCGTGTGGACAGAGGAGGCAGACACCCATCTGCCCATGATGTGATC981

TyrArgValAspArgGlyGlyArgHisProSerAlaHisAspValIle

147014751480

CTGGAAGGTGCTGGTCTACGGATCACAGCTCCCTTGATGCCACTTGGC1029

LeuGluGlyAlaGlyLeuArgIleThrAlaProLeuMetProLeuGly

148514901495

AAGACACTGCCTTGTGGGCTCACCAAGACTTACACATTCAGGTTAAAT1077

LysThrLeuProCysGlyLeuThrLysThrTyrThrPheArgLeuAsn

150015051510

GAGCATCCAAGCAATAATTGGAGCCCCCAGCTGAGTTACTTTGAGTAT1125

GluHisProSerAsnAsnTrpSerProGlnLeuSerTyrPheGluTyr

1515152015251530

CGAAGGTTACTGCGGAATCTCACAGCCCTCCGCATCCGAGCTACATAT1173

ArgArgLeuLeuArgAsnLeuThrAlaLeuArgIleArgAlaThrTyr

153515401545

GGAGAATACAGTACTGGGTACATTGACAATGTGACCCTGATTTCAGCC1221

GlyGluTyrSerThrGlyTyrIleAspAsnValThrLeuIleSerAla

155015551560

CGCCCTGTCTCTGGAGCCCCAGCACCCTGGGTTGAACAGTGTATATGT1269

ArgProValSerGlyAlaProAlaProTrpValGluGlnCysIleCys

156515701575

CCTGTTGGGTACAAGGGGCAATTCTGCCAGGATTGTGCTTCTGGCTAC1317

ProValGlyTyrLysGlyGlnPheCysGlnAspCysAlaSerGlyTyr

158015851590

AAGAGAGATTCAGCGAGACTGGGGCCTTTTGGCACCTGTATTCCTTGT1365

LysArgAspSerAlaArgLeuGlyProPheGlyThrCysIleProCys

1595160016051610

AACTGTCAAGGGGGAGGGGCCTGTGATCCAGACACAGGAGATTGTTAT1413

AsnCysGlnGlyGlyGlyAlaCysAspProAspThrGlyAspCysTyr

161516201625

TCAGGGGATGAGAATCCTGACATTGAGTGTGCTGACTGCCCAATTGGT1461

SerGlyAspGluAsnProAspIleGluCysAlaAspCysProIleGly

163016351640

TTCTACAACGATCCGCACGACCCCCGCAGCTGCAAGCCATGTCCCTGT1509

PheTyrAsnAspProHisAspProArgSerCysLysProCysProCys

164516501655

CATAACGGGTTCAGCTGCTCAGTGATTCCGGAGACGGAGGAGGTGGTG1557

HisAsnGlyPheSerCysSerValIleProGluThrGluGluValVal

166016651670

TGCAATAACTGCCCTCCCGGGGTCACCGGTGCCCGCTGTGAGCTCTGT1605

CysAsnAsnCysProProGlyValThrGlyAlaArgCysGluLeuCys

1675168016851690

GCTGATGGCTACTTTGGGGACCCCTTTGGTGAACATGGCCCAGTGAGG1653

AlaAspGlyTyrPheGlyAspProPheGlyGluHisGlyProValArg

169517001705

CCTTGTCAGCCCTGTCAATGCAACAGCAATGTGGACCCCAGTGCCTCT1701

ProCysGlnProCysGlnCysAsnSerAsnValAspProSerAlaSer

171017151720

GGGAATTGTGACCGGCTGACAGGCAGGTGTTTGAAGTGTATCCACAAC1749

GlyAsnCysAspArgLeuThrGlyArgCysLeuLysCysIleHisAsn

172517301735

ACAGCCGGCATCTACTGCGACCAGTGCAAAGCAGGCTACTTCGGGGAC1797

ThrAlaGlyIleTyrCysAspGlnCysLysAlaGlyTyrPheGlyAsp

174017451750

CCATTGGCTCCCAACCCAGCAGACAAGTGTCGAGCTTGCAACTGTAAC1845

ProLeuAlaProAsnProAlaAspLysCysArgAlaCysAsnCysAsn

1755176017651770

CCCATGGGCTCAGAGCCTGTAGGATGTCGAAGTGATGGCACCTGTGTT1893

ProMetGlySerGluProValGlyCysArgSerAspGlyThrCysVal

177517801785

TGCAAGCCAGGATTTGGTGGCCCCAACTGTGAGCATGGAGCATTCAGC1941

CysLysProGlyPheGlyGlyProAsnCysGluHisGlyAlaPheSer

179017951800

TGTCCAGCTTGCTATAATCAAGTGAAGATTCAGATGGATCAGTTTATG1989

CysProAlaCysTyrAsnGlnValLysIleGlnMetAspGlnPheMet

180518101815

CAGCAGCTTCAGAGAATGGAGGCCCTGATTTCAAAGGCTCAGGGTGGT2037

GlnGlnLeuGlnArgMetGluAlaLeuIleSerLysAlaGlnGlyGly

182018251830

GATGGAGTAGTACCTGATACAGAGCTGGAAGGCAGGATGCAGCAGGCT2085

AspGlyValValProAspThrGluLeuGluGlyArgMetGlnGlnAla

1835184018451850

GAGCAGGCCCTTCAGGACATTCTGAGAGATGCCCAGATTTCAGAAGGT2133

GluGlnAlaLeuGlnAspIleLeuArgAspAlaGlnIleSerGluGly

185518601865

GCTAGCAGATCCCTTGGTCTCCAGTTGGCCAAGGTGAGGAGCCAAGAG2181

AlaSerArgSerLeuGlyLeuGlnLeuAlaLysValArgSerGlnGlu

187018751880

AACAGCTACCAGAGCCGCCTGGATGACCTCAAGATGACTGTGGAAAGA2229

AsnSerTyrGlnSerArgLeuAspAspLeuLysMetThrValGluArg

188518901895

GTTCGGGCTCTGGGAAGTCAGTACCAGAACCGAGTTCGGGATACTCAC2277

ValArgAlaLeuGlySerGlnTyrGlnAsnArgValArgAspThrHis

190019051910

AGGCTCATCACTCAGATGCAGCTGAGCCTGGCAGAAAGTGAAGCTTCC2325

ArgLeuIleThrGlnMetGlnLeuSerLeuAlaGluSerGluAlaSer

1915192019251930

TTGGGAAACACTAACATTCCTGCCTCAGACCACTACGTGGGGCCAAAT2373

LeuGlyAsnThrAsnIleProAlaSerAspHisTyrValGlyProAsn

193519401945

GGCTTTAAAAGTCTGGCTCAGGAGGCCACAAGATTAGCAGAAAGCCAC2421

GlyPheLysSerLeuAlaGlnGluAlaThrArgLeuAlaGluSerHis

195019551960

GTTGAGTCAGCCAGTAACATGGAGCAACTGACAAGGGAAACTGAGGAC2469

ValGluSerAlaSerAsnMetGluGlnLeuThrArgGluThrGluAsp

196519701975

TATTCCAAACAAGCCCTCTCACTGGTGCGCAAGGCCCTGCATGAAGGA2517

TyrSerLysGlnAlaLeuSerLeuValArgLysAlaLeuHisGluGly

›(A) NAME/KEY: CDS · 2 of 2

198019851990

GTCGGAAGCGGAAGCGGTAGCCCGGACGGTGCTGTGGTGCAAGGGCTT2565

ValGlySerGlySerGlySerProAspGlyAlaValValGlnGlyLeu

1995200020052010

GTGGAAAAATTGGAGAAAACCAAGTCCCTGGCCCAGCAGTTGACAAGG2613

ValGluLysLeuGluLysThrLysSerLeuAlaGlnGlnLeuThrArg

201520202025

GAGGCCACTCAAGCGGAAATTGAAGCAGATAGGTCTTATCAGCACAGT2661

GluAlaThrGlnAlaGluIleGluAlaAspArgSerTyrGlnHisSer

203020352040

CTCCGCCTCCTGGATTCAGTGTCTCCGCTTCAGGGAGTCAGTGATCAG2709

LeuArgLeuLeuAspSerValSerProLeuGlnGlyValSerAspGln

204520502055

TCCTTTCAGGTGGAAGAAGCAAAGAGGATCAAACAAAAAGCGGATTCA2757

SerPheGlnValGluGluAlaLysArgIleLysGlnLysAlaAspSer

206020652070

CTCTCAAGCCTGGTAACCAGGCATATGGATGAGTTCAAGCGTACACAA2805

LeuSerSerLeuValThrArgHisMetAspGluPheLysArgThrGln

2075208020852090

AAGAATCTGGGAAACTGGAAAGAAGAAGCACAGCAGCTCTTACAGAAT2853

LysAsnLeuGlyAsnTrpLysGluGluAlaGlnGlnLeuLeuGlnAsn

209521002105

GGAAAAAGTGGGAGAGAGAAATCAGATCAGCTGCTTTCCCGTGCCAAT2901

GlyLysSerGlyArgGluLysSerAspGlnLeuLeuSerArgAlaAsn

211021152120

CTTGCTAAAAGCAGAGCACAAGAAGCACTGAGTATGGGCAATGCCACT2949

LeuAlaLysSerArgAlaGlnGluAlaLeuSerMetGlyAsnAlaThr

212521302135

TTTTATGAAGTTGAGAGCATCCTTAAAAACCTCAGAGAGTTTGACCTG2997

PheTyrGluValGluSerIleLeuLysAsnLeuArgGluPheAspLeu

214021452150

CAGGTGGACAACAGAAAAGCAGAAGCTGAAGAAGCCATGAAGAGACTC3045

GlnValAspAsnArgLysAlaGluAlaGluGluAlaMetLysArgLeu

2155216021652170

TCCTACATCAGCCAGAAGGTTTCAGATGCCAGTGACAAGACCCAGCAA3093

SerTyrIleSerGlnLysValSerAspAlaSerAspLysThrGlnGln

217521802185

GCAGAAAGAGCCCTGGGGAGCGCTGCTGCTGATGCACAGAGGGCAAAG3141

AlaGluArgAlaLeuGlySerAlaAlaAlaAspAlaGlnArgAlaLys

219021952200

AATGGGGCCGGGGAGGCCCTGGAAATCTCCAGTGAGATTGAACAGGAG3189

AsnGlyAlaGlyGluAlaLeuGluIleSerSerGluIleGluGlnGlu

220522102215

ATTGGGAGTCTGAACTTGGAAGCCAATGTGACAGCAGATGGAGCCTTG3237

IleGlySerLeuAsnLeuGluAlaAsnValThrAlaAspGlyAlaLeu

222022252230

GCCATGGAAAAGGGACTGGCCTCTCTGAAGAGTGAGATGAGGGAAGTG3285

AlaMetGluLysGlyLeuAlaSerLeuLysSerGluMetArgGluVal

2235224022452250

GAAGGAGAGCTGGAAAGGAAGGAGCTGGAGTTTGACACGAATATGGAT3333

GluGlyGluLeuGluArgLysGluLeuGluPheAspThrAsnMetAsp

225522602265

GCAGTACAGATGGTGATTACAGAAGCCCAGAAGGTTGATACCAGAGCC3381

AlaValGlnMetValIleThrGluAlaGlnLysValAspThrArgAla

227022752280

AAGAACGCTGGGGTTACAATCCAAGACACACTCAACACATTAGACGGC3429

LysAsnAlaGlyValThrIleGlnAspThrLeuAsnThrLeuAspGly

228522902295

CTCCTGCATCTGATGGGTATGTGAACCCACAACCCACAACCTTCCAGCTCCATG3483

LeuLeuHisLeuMetGlyMet*

23002305

CTCCAGGGCTTTGCTCCAGAACACTCACTATACCTAGCCCCAGCAAAGGGGAGTCTCAGC3543

TTTCCTTAAGGATATCAGTAAATGTGCTTTGTTTCCAGGCCCAGATAACTTTCGGCAGGT3603

TCCCTTACATTTACTGGACCCTGTTTTACCGTTGCTAAGATGGGTCACTGAACACCTATT3663

GCACTTGGGGGTAAAGGTCTGTGGGCCAAAGAACAGGTGTATATAAGCAACTTCACAGAA3723

CACGAGACAGCTTGGGAATCCTGCTAAAGAGTCTGGCCTGGACCCTGAGAAGCCAGTGGA3783

CAGTTTTAAGCAGAGGAATAACATCACCACTGTATATTTCAGAAAGATCACTAGGGCAGC3843

CGAGTGGAGGAAAGCTTGAAGAGGGGGTTAGAGAGAAGGCAGGTTGAGACTACTTAAGAT3903

ATTGTTGAAATAATTGAAGAGAGAAATGACAGGAGCCTGCTCTAAGGCAGTAGAATGGTG3963

GCTGGGAAGATGTGAAGGAAGATTTTCCCAGTCTGTGAAGTCAAGAATCACTTGCCGGCC4023

GGGTGTGGTGGCTCACGCCTGTAATTCTAGCACTTTGGGAGACTGAAGCGGGTGGATCAC4083

CCGAGGTCAGGAGTTGAAGACCAGCCTGGCCAACATGGTGAAACCCTGTCTCTACTAAAA4143

GTACAAAAATTAGCTGGATGATGGTGGTGGGCGCCTGTAATTCCAGCTACTCAGGAGTCT4203

GAGGCAGGAGAATCGCTTGAACCCAGGAGGCGAGGTTACAGTGAGCCAAGATTGCACCAC4263

TGCTCTTCCAGCCTGGGAACAGAGAGACTGCCTAAAAAAAAAAAAAAAAAAAA4316

(2) INFORMATION FOR SEQ ID NO:15:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 1111 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

MetProAlaLeuTrpLeuGlyCysCysLeuCysPheSerLeuLeuLeu

151015

ProAlaAlaArgAlaThrSerArgArgGluValCysAspCysAsnGly

202530

LysSerArgGlnCysIlePheAspArgGluLeuHisArgGlnThrGly

354045

AsnGlyPheArgCysLeuAsnCysAsnAspAsnThrAspGlyIleHis

505560

CysGluLysCysLysAsnGlyPheTyrArgHisArgGluArgAspArg

65707580

CysLeuProCysAsnCysAsnSerLysGlySerLeuSerAlaArgCys

859095

AspAsnSerGlyArgCysSerCysLysProGlyValThrGlyAlaArg

100105110

CysAspArgCysLeuProGlyPheHisMetLeuThrAspAlaGlyCys

115120125

ThrGlnAspGlnArgLeuLeuAspSerLysCysAspCysAspProAla

130135140

GlyIleAlaGlyProCysAspAlaGlyArgCysValCysLysProAla

145150155160

ValThrGlyGluArgCysAspArgCysArgSerGlyTyrTyrAsnLeu

165170175

AspGlyGlyAsnProGluGlyCysThrGlnCysPheCysTyrGlyHis

180185190

SerAlaSerCysArgSerSerAlaGluTyrSerValHisLysIleThr

195200205

SerThrPheHisGlnAspValAspGlyTrpLysAlaValGlnArgAsn

210215220

GlySerProAlaLysLeuGlnTrpSerGlnArgHisGlnAspValPhe

225230235240

SerSerAlaGlnArgLeuAspProValTyrPheValAlaProAlaLys

245250255

PheLeuGlyAsnGlnGlnValSerTyrGlyGlnSerLeuSerPheAsp

260265270

TyrArgValAspArgGlyGlyArgHisProSerAlaHisAspValIle

275280285

LeuGluGlyAlaGlyLeuArgIleThrAlaProLeuMetProLeuGly

290295300

LysThrLeuProCysGlyLeuThrLysThrTyrThrPheArgLeuAsn

305310315320

GluHisProSerAsnAsnTrpSerProGlnLeuSerTyrPheGluTyr

325330335

ArgArgLeuLeuArgAsnLeuThrAlaLeuArgIleArgAlaThrTyr

340345350

GlyGluTyrSerThrGlyTyrIleAspAsnValThrLeuIleSerAla

355360365

ArgProValSerGlyAlaProAlaProTrpValGluGlnCysIleCys

370375380

ProValGlyTyrLysGlyGlnPheCysGlnAspCysAlaSerGlyTyr

385390395400

LysArgAspSerAlaArgLeuGlyProPheGlyThrCysIleProCys

405410415

AsnCysGlnGlyGlyGlyAlaCysAspProAspThrGlyAspCysTyr

420425430

SerGlyAspGluAsnProAspIleGluCysAlaAspCysProIleGly

435440445

PheTyrAsnAspProHisAspProArgSerCysLysProCysProCys

450455460

HisAsnGlyPheSerCysSerValIleProGluThrGluGluValVal

465470475480

CysAsnAsnCysProProGlyValThrGlyAlaArgCysGluLeuCys

485490495

AlaAspGlyTyrPheGlyAspProPheGlyGluHisGlyProValArg

500505510

ProCysGlnProCysGlnCysAsnSerAsnValAspProSerAlaSer

515520525

GlyAsnCysAspArgLeuThrGlyArgCysLeuLysCysIleHisAsn

530535540

ThrAlaGlyIleTyrCysAspGlnCysLysAlaGlyTyrPheGlyAsp

545550555560

ProLeuAlaProAsnProAlaAspLysCysArgAlaCysAsnCysAsn

565570575

ProMetGlySerGluProValGlyCysArgSerAspGlyThrCysVal

580585590

CysLysProGlyPheGlyGlyProAsnCysGluHisGlyAlaPheSer

595600605

CysProAlaCysTyrAsnGlnValLysIleGlnMetAspGlnPheMet

610615620

GlnGlnLeuGlnArgMetGluAlaLeuIleSerLysAlaGlnGlyGly

625630635640

AspGlyValValProAspThrGluLeuGluGlyArgMetGlnGlnAla

645650655

GluGlnAlaLeuGlnAspIleLeuArgAspAlaGlnIleSerGluGly

660665670

AlaSerArgSerLeuGlyLeuGlnLeuAlaLysValArgSerGlnGlu

675680685

AsnSerTyrGlnSerArgLeuAspAspLeuLysMetThrValGluArg

690695700

ValArgAlaLeuGlySerGlnTyrGlnAsnArgValArgAspThrHis

705710715720

ArgLeuIleThrGlnMetGlnLeuSerLeuAlaGluSerGluAlaSer

725730735

LeuGlyAsnThrAsnIleProAlaSerAspHisTyrValGlyProAsn

740745750

GlyPheLysSerLeuAlaGlnGluAlaThrArgLeuAlaGluSerHis

755760765

ValGluSerAlaSerAsnMetGluGlnLeuThrArgGluThrGluAsp

770775780

TyrSerLysGlnAlaLeuSerLeuValArgLysAlaLeuHisGluGly

785790795800

ValGlySerGlySerGlySerProAspGlyAlaValValGlnGlyLeu

805810815

ValGluLysLeuGluLysThrLysSerLeuAlaGlnGlnLeuThrArg

820825830

GluAlaThrGlnAlaGluIleGluAlaAspArgSerTyrGlnHisSer

835840845

LeuArgLeuLeuAspSerValSerProLeuGlnGlyValSerAspGln

850855860

SerPheGlnValGluGluAlaLysArgIleLysGlnLysAlaAspSer

865870875880

LeuSerSerLeuValThrArgHisMetAspGluPheLysArgThrGln

885890895

LysAsnLeuGlyAsnTrpLysGluGluAlaGlnGlnLeuLeuGlnAsn

900905910

GlyLysSerGlyArgGluLysSerAspGlnLeuLeuSerArgAlaAsn

915920925

LeuAlaLysSerArgAlaGlnGluAlaLeuSerMetGlyAsnAlaThr

930935940

PheTyrGluValGluSerIleLeuLysAsnLeuArgGluPheAspLeu

945950955960

GlnValAspAsnArgLysAlaGluAlaGluGluAlaMetLysArgLeu

965970975

SerTyrIleSerGlnLysValSerAspAlaSerAspLysThrGlnGln

980985990

AlaGluArgAlaLeuGlySerAlaAlaAlaAspAlaGlnArgAlaLys

99510001005

AsnGlyAlaGlyGluAlaLeuGluIleSerSerGluIleGluGlnGlu

101010151020

IleGlySerLeuAsnLeuGluAlaAsnValThrAlaAspGlyAlaLeu

1025103010351040

AlaMetGluLysGlyLeuAlaSerLeuLysSerGluMetArgGluVal

104510501055

GluGlyGluLeuGluArgLysGluLeuGluPheAspThrAsnMetAsp

106010651070

AlaValGlnMetValIleThrGluAlaGlnLysValAspThrArgAla

107510801085

LysAsnAlaGlyValThrIleGlnAspThrLeuAsnThrLeuAspGly

109010951100

LeuLeuHisLeuMetGlyMet

11051110

(2) INFORMATION FOR SEQ ID NO:16:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligomer primers"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GAGCGCAGAGTGAGAACCAC20

(2) INFORMATION FOR SEQ ID NO:17:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligomer primers"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ACTGTATTCTGCAGAGCTGC20

(2) INFORMATION FOR SEQ ID NO:18:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "oligomer primers"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TTCCTTTCCCCTACCTTGTG20

(2) INFORMATION FOR SEQ ID NO:19:

›(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

›(A) DESCRIPTION: /desc = "OLIGOMER PRIMER"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TGTGGAAGCCTGGCAGACAT20

__________________________________________________________________________

Claims

30 · 3 independent · depth 2

30 granted claims

›1.independentA method for detecting kalinin/laminin 5 expression in cells and tissue comprising: a) hybridizing the cells and tissue with an effective amount of a …+9

›11.independentA method for detecting the presence of invasive cells in tissue comprising: a) hybridizing the tissue with an effective amount of a nucleic acid probe…+9

›21.independentA method for monitoring the presence of invasive cells in tissue comprising: a) hybridizing the tissue with an effective amount of a nucleic acid prob…+9

Classifications

8 codes

IPC · International Patent Classification

Section C — Chemistry; metallurgy

C12Q1/6886
C07K16/28
C12Q1/68

USPC · US Patent Classification

435/6435/91.2435/320.1536/24.3536/23.1

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

2.9 y

1,057 days filing → grant

Office actions

on the grant's record

Examiner

W. Gary Jones

art unit 187 · TC 1800

Law firm

Law firm · Log in to unlock

Citations: 21 back · 14 forward

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Worldwide family

15 members · 9 offices

this patentIP5 & PCTother officessolid = grantedhover for detail · click to open

Members

DOCDB simple family 23233705

Offices

US · EP · WO

Granted

9 of 15

grant date present

Non-English titles

shown as filed, never translated

›IP5 & PCT — 7 members

Office	Publication	Kind	Published	Filed	Status	Title
USthis patent	US-5660982-A	A	26 Aug 1997	4 Oct 1994	granted	Laminin chains: diagnostic uses
US	US-6143505-A	A	7 Nov 2000	18 Feb 1997	granted	Laminin chains: diagnostic and therapeutic use
US	US-2003100529-A1	A1	29 May 2003	26 Aug 2002	published	Laminin chains: diagnostic and therapeutic use
US	US-2005048518-A1	A1	3 Mar 2005	11 Dec 2003	published	Laminin chains: diagnostic and therapeutic use
EP	EP-0784703-A1	A1	23 Jul 1997	4 Oct 1995	published	Lamanin-ketten: diagnostische und therapeutische verwendungde
EP	EP-0784703-B1	B1	14 Jul 1999	4 Oct 1995	granted	Lamanin-ketten: diagnostische und therapeutische verwendungde
WO	WO-9610646-A1	A1	11 Apr 1996	4 Oct 1995	published	Laminin chains: diagnostic and therapeutic use

›Other offices — 8 members

Office	Publication	Kind	Published	Filed	Status	Title
AT	AT-E182180-T1	T1	15 Jul 1999	4 Oct 1995	granted	Lamanin-ketten: diagnostische und therapeutische verwendungde
AU	AU-3745195-A	A	26 Apr 1996	4 Oct 1995	published	Laminin chains: diagnostic and therapeutic use
AU	AU-699183-B2	B2	26 Nov 1998	4 Oct 1995	granted	Laminin chains: diagnostic and therapeutic use
DE	DE-69510810-D1	D1	19 Aug 1999	4 Oct 1995	granted	Lamanin-ketten: diagnostische und therapeutische verwendungde
DE	DE-69510810-T2	T2	4 Nov 1999	4 Oct 1995	granted	Lamanin-ketten: diagnostische und therapeutische verwendungde
DK	DK-0784703-T3	T3	29 Nov 1999	4 Oct 1995	granted	Lamininkæder: Diagnostisk og terapeutisk anvendelseda
ES	ES-2133813-T3	T3	16 Sep 1999	4 Oct 1995	granted	Cadenas de lamininas: diagnostico y uso terapeutico.es
GR	GR-3031488-T3	T3	31 Jan 2000	8 Oct 1999	published	Laminin chains: diagnostic and therapeutic use

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.